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1. INTRODUCTION 
 
1.1. NOVEL DRUG DELIVERY SYSTEM (Bankar G.S and Rhodes C.T., 2009; 
Brahmankar  D.M and Jaiswal S.B., 1995; Chein Y.W., 1995) 
The goal of a sustained release dosage form is to maintain therapeutic blood or 
tissue levels of the drug for an extended and specified period of time. This is generally 
accomplished by attempting to obtain "zero-order" release from the dosage form. Zero-
order release constitutes drug release from the dosage form which is independent of the 
amount of drug in the delivery system (i.e. a constant release rate). Sustained-release 
systems generally do not attain this type of release and usually try to mimic zero-order 
release by providing drug in a slow first-order fashion   (i.e., concentration release 
dependent). Systems that are designated as prolonged release can also be considered as 
attempts at achieving sustained-release delivery. 
The term ―Controlled- release drug product‖ has been used to describe various 
types of oral extended release rate dosage forms, including sustained release (SR), 
sustained action, prolonged action, long action and retarded release. These terms for 
extended release dosage forms were introduced by drug companies to reflect a special 
design for producing an extended release (ER) dosage form or used as a marketing term. 
In the last two-three decades interest in sustained release drug delivery systems is 
remarkably increasing. This has been due to various factors viz. 
 Developing new drug entities. 
 Expiration of international patents. 
 Discovery of new polymeric materials suitable for prolonging the drug release. 
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 Need of therapeutic efficacy and safety achieved by sustained release drug 
delivery. 
The subject of sustain release has been reviewed by various authors. Several 
books have been published on it. These reviews and books provide not only the 
mechanisms and technology of production of dosage forms but also the information on 
clinical evidence and performance. 
There are many definitions of sustained release but the simplest definition is ―Any 
drug or dosage form or medication that prolongs the therapeutic activity of drug’’. The 
overall objective is that, once the drug-carrier material has been injected or otherwise 
implanted or taken orally into the body, the drug is released at a predetermined rate for 
some desired period of time. Controlled release technology is relatively new field and as 
a consequence, research in this field has been extremely fertile and has produced many 
discoveries. 
Non-immediate release delivery systems may be divided conveniently into 4 
categories, 
A. Delayed release 
B. Sustained release 
a) Controlled release 
b) Prolonged release 
C.   Site- specific release 
D.   Receptor release 
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Delayed – release systems are those that use repetitive, intermittence dosing of a 
drug from one or more immediate release units incorporated into a single dosage forms to 
make delayed action. Example: Repeat- action tablets and capsules, enteric coated tablets 
where timed release achieved by a barrier coating. 
Sustained- release systems includes any drug delivery system that achieves slow 
release of drug over an extended period of time. 
Controlled release systems are those systems which are successful maintaining 
constant drug levels in blood or target release (i.e.) release rate of drug occurs in 
controlled manner. 
Prolonged released systems only extends the duration of action and drug release 
that achieved by conventional drug delivery. 
Site specific and receptor release refers to targeting of drug directly to a certain 
biological location. In the case of site- specific release, the target is a certain organ or 
tissue, for receptor release, the target is the particular receptor for a drug within an organ 
or tissue. 
Control release system differs from Sustain release system
 
which simply prolongs 
the drug release and hence plasma drug levels for an extended period of time (i.e. not 
necessarily at a predetermined rate). Thus the chief objective of most products should be 
controlled delivery to reduce dosing frequency to an extent that once daily dose is 
sufficient for therapeutic management through a uniform plasma concentration at steady 
state. 
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Figure 1.1 A hypothetical plasma concentration Vs time profile from conventional 
multiple and single doses of sustained release drug delivery formulations. 
 
 
1.2 ANATOMY AND PHYSIOLOGY OF STOMACH (Tortora G. and Derrickson 
B., 2003; Ramesh R.P. and Mahesh C.P.,2009; Aulton M.E., 2002) 
Stomach is an organ with capacity for storage and mixing. It is located just below 
the diaphragm in the epigastric and left hydrochondriac region of the abdomen.  
      The stomach is anatomically divided into three parts:  
 Fundus 
 Body 
 Pylorus (Antrum) 
Stomach is made up of fundus and body regions. They are capable of displaying a 
large expansion to accommodate food without much increase in intragastric pressure. 
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Stomach lining is devoid of villi and it consists of considerable number of gastric 
pits that contribute to storage capacity of the stomach. Ant rum region is responsible for 
the mixing and grinding of gastric content. There are two main secretions: mucus and 
acid, produced by specialized cell in stomach lining. Mucus is secreted by goblet cells 
and gastric acid by parietal cells (oxyntric) The Mucus spread and cover the rest of GI 
tract. Under fasting condition the stomach is a collapsed bag with a residual volume of 50 
ml and contains a small amount of gastric fluid (pH 1-3) and air. 
 
Figure 1.2 Structure of Stomach 
 Physiology: 
 The physiology and disease state of stomach has a direct effect on design of 
controlled drug delivery system because drug is absorbed from and enters into site of 
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action. Factors such as pH, nature and volume of gastric secretions and gastric mucosa 
play an important role in drug release and absorption.  
 
 pH:  
 Environmental pH affects the performance of orally administered drugs. The pH 
of stomach in fasted condition is about 1.5 to 2 and in fed conditions it is usually 2 to 6. 
A large volume of water administered with oral dosage form changes the pH of stomach 
to pH of water initially. This change occurs because stomach does not have enough time 
to produce sufficient quantity of acid before emptying of liquid from the stomach.            
     Table 1.1 Anatomical difference between different regions of the GIT 
Particulars Stomach 
Small 
intestine 
Large intestine Rectum 
pH range 1-3 5-7.5 7.9-8.0 7.5-8.0 
Length (cm) 20 285 110 20 
Diameter (cm) 15 2.5 5 2.5 
Surface area (m
2
) 0.1-0.2 200 0.15 0.02 
Blood flow (L/min) 0.15 1.0 0.02 - 
Transit time (hrs) 1-5 3-6 6-12 6-12 
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 Volume: 
The resting volume of stomach is about 25-52 ml. Gastric volume is important for 
dissolution of the dosage forms in-vivo. Meyer et al. conducted an experiment to study 
the effect of gastric fluid volume on absorption of controlled release theophylline dosage 
form in human beings. During this experiment they measured the gastric fluid volume of 
each subject. They estimated the mean gastric fluid volume in normal and achlorhydric 
subjects. The mean volume recovered by gastric aspiration over three consecutive, 15 
min. time periods was 61+51 ml in achlorhydric subjects and 98+38 ml in normal 
subjects. Thus, there is such a large volume difference in gastric secretions that would 
significantly affect in-vivo dissolution of drugs. 
 
 Gastric mucosa:  
  Simple columnar epithelial cells line the entire mucosal surface of the stomach. 
Mucus, parietal and peptic cells are present in the body of stomach. These cells are 
associated with different functions. The parietal cells secrete acid whereas the peptic cells 
secrete precursor for pepsin. The surface mucosal cells secrete the mucus and 
bicarbonate. They protect the stomach from digestion by pepsin and from the adverse 
effects of hydrochloric acid. As mucus has lubricating effect, it allows chyme to move 
freely through the digestive system. 
 
 Gastric secretion:      
Acids, pepsin, gastrin, mucus and some other enzymes are the secretions of   the 
stomach. Normal adults produce a basal secretion up to 60 ml with approximately 4 milli 
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mol of hydrogen ions every hour. Other potent stimulators of gastric acid are the 
hormones like gastrin, peptides, amino acids and gastric distention. 
 
 Liquid in fasted and fed conditions: 
 Volumes of liquids affect gastric emptying of liquids, larger the volume, faster the 
emptying. Gastric emptying of small volumes like 100 ml or less is governed by the 
MMC cycle whereas large volumes of liquids 200 ml or more are emptied out 
immediately after administration.  
 
 Effect of food on gastric secretion: 
Type of meal and its caloric content, volume, viscosity and co-administered drugs 
affect gastric secretions and gastric emptying time. The rate of emptying primarily 
depends on caloric contents of the ingested meal. It does not differ for proteins, fats and 
carbohydrates as long as their caloric contents are the same.  
 
 Gastric motility: (Jain N.K., 2004) 
The pattern series of motility is distinct in fasted and fed states. During the fasting 
state an inter digestive series of electrical events takes place, which cycle both through 
stomach and intestine every 2 to 3 hrs. This is called the interdigestive myoelectric cycle 
or migrating myoelectric cycle (MMC), which is divided into following 4 phases.  
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Figure 1.3 Four phases of myoelectric cycle 
 
 Phase I (basal): Lasts for 30 to 60 minutes. Contractions can be characterized by a 
lack of secretary, electrical, and contractile activity. 
 Phase II (preburst): Lasts for 20 to 40 minutes. With intermittent action potential 
and contractions. 
 Phase III (burst): Lasts for 10 to 20 minutes. Includes intense and regular 
contractions. It is due to this wave that all undigested material is swept out of the 
stomach down to the small intestine. It is also known as housekeeper wave. 
 Phase IV: Lasts for 0 to 5 minutes. 
After the ingestion of mixed meal, the pattern of contractions changes from fasted to 
fed state. It comprises continuous contractions as in phase II of fasted state. These 
contractions result in reducing the size of food particles (<1 mm), which are propelled 
toward pylorus. During fed state onset of MMC is delayed resulting in slowdown of 
gastric emptying rate. 
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 Gastric emptying: 
Particle size and feeding state strongly affect the residence time of particles in 
stomach. Some other factors affecting gastric emptying are as follows: 
Type of meal and its caloric content, volume, viscosity and co administered drugs. The 
rate of gastric emptying primarily depends on the caloric contents of the ingested meal. It 
does not differ for proteins, fats and carbohydrates as long as their caloric content is the 
same. 
 
 Solid In fasted and fed conditions: 
Tablets or capsules do not have any significant calorific value. Therefore, the stomach 
treats them as an indigestible material. It is known that particle smaller than 2 mm in size 
are emptied from the stomach quickly. The density of the solid dosage form also affects 
the gastric emptying time. The average time required for a dosage unit to traverse the GIT 
is 3–4 hours, although slight variations exist among various dosage forms. 
 
1.3 DRUG PROPERTIES RELEVANT TO SUSTAINED RELEASE 
FORMULATIONS   (Bankar G.S and Rhodes C.T., 2009; Robinson J.R and Lee V.H.L., 
2005) 
During design of sustained release delivery systems, variables such as the route of 
drug delivery, the type of delivery system, the disease being treated, the patient, the 
length of therapy and the properties of the drug, are considered of particular interest to 
the scientist designing the system are the constraints imposed by the properties of the 
drug.  
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These properties are classified as, 
A) Physicochemical properties  
B) Biological properties 
These properties have the greatest effect on the behavior of the drug in the delivery 
system and in the body. There is no clear-cut distinction between these two categories 
since the biological properties of a drug are a function of its physicochemical properties. 
By definition, physicochemical properties are those that can be determined from in-vitro 
experiments and biological properties will be those that result from typical 
pharmacokinetic studies of the absorption, distribution, metabolism, and excretion 
(ADME) characteristics of a drug and those resulting from pharmacological studies. 
 
A) Physicochemical Properties
 
a) Dose Size 
b) Aqueous Solubility and pKa 
c) Partition Coefficient 
d) Drug Stability 
e) Molecular Size and Diffusivity 
f) Drug Protein Binding 
B) Biological Properties
 
a) Absorption 
b) Distribution 
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c) Metabolism 
d) Elimination and Biological Half-Life 
e) Margin of Safety (Toxicity). 
 
A. Physiochemical properties 
a) Dose size: For orally administered drugs, there is an upper limit to the bulk size of 
the dose to be administered. In general, a single dose of 0.5 – 11.0 gm for 
conventional dosage form is considered maximal. 
b) Aqueous Solubility: Extremes in aqueous solubility are under desirable in the 
preparation of a SR product. For drug with low water solubility, it will be difficult to 
incorporate into a SR formulation. The lower limit of solubility for such product has 
been reported to be 0.1 mg/ml. 
c) Partition Co-efficient: Drug that are very lipid soluble or water soluble i.e. 
extremes in partition co-efficient, will demonstrate either low flux in to the tissues or 
rapid flux followed by accumulation in the tissues. Both extremes are undesirable for 
a SR system Eg: Phenothiazines class of compounds is highly lipid soluble.  
d) Drug Stability : since most oral SR systems, by necessity are designed to release 
their contents over much of the length of the GIT, drugs which are unstable in the 
environment of the intestine might be difficult to formulate into prolonged release 
systems. 
Eg: Propanthdine and Probanthine. 
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B. Biological properties 
         a)  Absorption:  Drugs that are slowly absorbed or absorbed with variable absorption 
rate are poor candidates for SR systems. For oral dosage forms the lower limit on the 
absorption rate constant  in the range of 0.17 to 0.23 hr
-1
(assuming GI transit time of 
8-12 hr
-1
). 
b) Metabolism: Drugs that are significantly metabolized, especially in region of small 
intestine, can show decreased bioavailability from SR dosage forms, because less 
total drug is presented to enzymatic process during a specific period. This allows 
more complete conversion of drug to its metabolite. 
c) Therapeutic Index:  Drugs with a narrow therapeutic range which require precise 
control over the blood levels of the drug are unsuitable for SR dosage forms. 
d) Half Life: The biological half life and duration of action of drug obviously plays a 
major role in considering a drug for SR systems. Drugs with a very short half life 
(>2 hours) require large amounts of drug to maintain sustained effects and drugs 
with longer life (<8 hours) because their effects are already sustained. 
 
1.4 GASTRO-RETENTIVE DOSAGE FORM (Jain N.K., 2004; Garg R. and Gupta 
G.D., 2008) 
One of the most feasible approaches for achieving a prolonged and predictable 
drug delivery in the GI tract is to control the gastric residence time (GRT), by using 
gastro-retentive dosage forms (GRDFs). GRDFs can remain in the gastric region for 
several hours and hence, prolong the gastric residence time of drug. GRDFs offers 
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several advantages over immediate release dosage form, including the minimization of 
fluctuations in drug concentration in plasma and at the site of action over prolonged 
periods of time, resulting in optimized therapeutic efficiencies and reduce the side effect, 
reduction of total dose administered and reduction of administration frequency, leading to 
improved patient compliances. Gastro-retention helps to provide better availability of 
new products with new therapeutic possibilities and substantial benefits for patients as 
compared to the conventional tablet dosage form. 
An absorption window exists because of physiological, physicochemical, or  
biochemical factors. Drugs having site-specific absorption are difficult to design as oral 
CRDDS because only the drug released in the region preceding and in close vicinity to 
the absorption window is available for absorption.  
 
Figure 1.4 Comparison of (a) conventional and (b) gastroretentive drug delivery system 
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After crossing the absorption window, the released drug goes waste with 
negligible or no absorption (Figure 1.4a). This phenomenon considerably decreases the 
time available for drug absorption after its release and expose the success of the delivery 
system. The GRDDS can improve the controlled delivery of the drugs which exhibit an 
absorption window by continuously releasing the drug for a prolonged period before it 
reaches its absorption site, thus ensuring its optimal bioavailability (BA) (Figure 1.4b). 
 
1.5. FACTORS AFFECTING GASTRIC RETENTION (Anilkumar J.S. and Harinath 
M.N., 2008; Shweta A. et al., 2005) 
There are several factors that can affect gastric retention of an oral dosage form. These 
factors are as follows. 
 Density: The density of a dosage form affects the gastric emptying rate. A buoyant 
dosage form having a density of less than that of gastric fluids floats. Since it is 
away from the pyloric sphincter, the dosage unit is retained in the stomach for a 
prolonged period. 
 Size: Dosage form units with a diameter of less than 7.5 mm are reported to have an 
increased GRT compared with those with a diameter of 9.9 mm.  
 Age: Elderly people, especially those over 70, have a longer GRT. 
 Shape of dosage form: Ring and tetrahedron shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch (KPSI) are reported to have 
better GRT (90% to 100%) of 24 hours compared with other shapes. 
 Single or multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to failure 
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of units, allow co-administration of units with different release profiles or containing 
incompatible substances. It permits a larger margin of safety against dosage form 
failure compared with single unit dosage forms. 
 Fed or unfed state: Under fasting state, the GI motility is characterized by periods 
of strong motor activity or the migrating myoelectric complex (MMC) that occurs 
every 1.5 to 2 hours. The MMC sweeps undigested material from the stomach and, if 
the timing of administration of the formulation coincides with that of the MMC, the 
GRT of the unit can be expected to be very short. 
 Caloric content: GRT can increase by 4 to 10 hours with a meal that is high in 
proteins and fats. 
 Nature of meal: Feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of the stomach to a fed state thus, decreasing the gastric emptying 
rate and prolonging drug release. 
 Frequency of feed: GRT can increase by over 400 minutes when successive meals 
are given compare with single meals due to the low frequency of MMC. 
 Gender: Mean ambulatory GRT in males (3.4 ± 0.6 hours) is less compared with 
their age and race-matched female counterparts (4.6 ± 1.2 hours), regardless of the 
weight, height and body surface. 
 Posture: Gastric emptying is favored while standing and by lying on the right side 
since the normal curvature of the stomach provides a downhill path whereas, lying 
on the left side or in supine position, retard it. 
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 Disease states: Diseases like gastro enteritis, gastric ulcer, pyloric stenosis, diabetes 
and hypothyroidism retard gastric emptying while partial gastrectomy, duodenal 
ulcer. 
 
1.6. VARIOUS GASTRO-RETENTIVE DRUG DELIVERY SYSTEM (Sable V. et 
al.,2010; Mayavanshi A.V. and Gajjar S.S., 2008) 
Various approaches have been pursued to increase the retention of an oral dosage form in 
the stomach. These include: 
A. Bio adhesive delivery system 
B. Size increasing system/ Expandable system 
C. High density system 
D. Floating drug delivery system / Low density system 
A. Bioadhesive system: 
Bio adhesive system is adhering to mucosal surface of the stomach after the oral. This 
have high turnover rate of gastric mucus and resulting limited retention time. The 
disadvantage of this system is possibility of oesophageal binding. 
B. Sized increasing drug delivery system or swelling system: 
This dosage forms have initially small size and when enter in the stomach significantly 
increasing its size above the diameter of the pylorus. The expanded state should be 
achieved rapidly in order to prevent premature emptying through the pylorus. 
Conversely, the system should also guarantee their clearance from the stomach after 
predetermined time intervals to avoid accumulation upon multiple administrations. 
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Figure 1.5 Approaches of gastro retentive drug delivery system 
 
C. High-density system: 
This system accomplished by coating the drug with a heavy inert material such as barium 
sulphate, zinc oxide, titanium dioxide, iron powder etc. These coated pellets which have 
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density greater than that of stomach content (1.004 gm/cm
3
). This system having density 
of ~ 3 gm/cm
3
 is retained in the range of the stomach. 
 
Figure 1.6 Various approaches of gastro retentive drug delivery system 
 
D. Floating drug delivery system: 
Floating drug delivery system (FDDS) or hydro dynamically balanced system have a bulk 
density lower than gastric fluid and thus remain buoyant in the stomach without affecting 
the gastric emptying rate for a prolonged period of time. While the system is floating on 
the gastric contents, the drug is released slowly at a desired rate from the system. After 
the release of drug, the residual system is emptied from the stomach. This result in an 
increase in the GRT and a better control on fluctuation of drug concentration. 
 Non-effervescent floating microparticulates of Celecoxib Introduction 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 21 
 
1.7 TECHNOLOGICAL DEVELOPMENT IN FDDS (Bandyopadhyay A.K., 2008; 
Patil J.M., et al., 2006) 
Based on the mechanism of buoyancy, two distinctly different types, i.e. non-
effervescent and effervescent systems have been utilized in the development of FDDS.  
A.  Effervescent FDDS:  
 Effervescent system utilize matrices prepared with swellable polymers such as 
methocel or polysaccharides e.g., chitosan and effervescent components, e.g., sodium 
bicarbonate and citric or tartaric acid or matrices containing chambers of liquid that 
gasify at body temperature.  The matrices are fabricated so that upon arrival in the 
stomach, carbon dioxide is liberated by the acidity of the gastric contents and is 
entrapped in the gellified hydrocolloid. This produces an upward motion of dosage form 
and maintains its buoyancy. 
a. Multiple-unit oral floating drug delivery system: 
Recently a multiple–unit type of floating pill, which generates carbon dioxide gas, 
has been developed. The system consisted of sustained–release pills as seeds surrounded 
by double layers. The inner layer an effervescent layer containing both sodium 
bicarbonate and tartaric acid. The outer layer was a swellable membrane layer containing 
mainly polyvinyl acetate and purified shellac. Moreover, the effervescent layer was 
divided into two sub layers the sodium bicarbonate was contained in the inner sub layer 
and tartaric acid was in the outer layer.  
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Figure 1.7 Multiple unit oral floating drug delivery system 
 
When the swollen pills are formed, like balloons, they have a density much lower 
than 1.004 gm/cm
3
. The reaction was due to carbon dioxide generated by neutralization 
in the inner effervescent layer with the diffusion of water through the outer swellable 
membrane layer.  
             A floating system utilizing ion-exchange resins has been developed. The system 
consisted of resin beads, which were loaded with bicarbonate and a negatively charged 
drug that was bound to the resin. The resultant beads were then encapsulated in a semi 
permeable membrane to overcome rapid loss of carbon dioxide. Upon arrival in the acidic 
environment of stomach, an exchange of chloride and bicarbonate ion takes place, as it is 
expected. As result of this reaction, carbon dioxide was released and trapped in the 
membrane, thereby, carrying beads toward the top of gastric contents and producing a 
floating layer of resin beads. In contrast, the uncoated beads sink quickly. Radioactivity 
measurement by scintigraphy showed that gastric residence was substantially prolonged, 
compared with a control, when the system was given after a light, mainly liquid meal.  
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Figure 1.8  Mechanism of effervescent drug delivery system 
 
           Furthermore, the system was capable of slow release of drug, a Property which 
widens the scope of such floating system for SR preparation of drugs possessing negative 
charge since they can be easily bound to the resin in combination with bicarbonate ions. 
Two patents on FDDS issued to the Alza Corporation disclosed drug delivery devices for 
the controlled and continuous administration of medicinal agents. The above figure 
shows mechanism of floating of effervescent drug delivery system. 
 
b. Inflatable gastrointestinal drug delivery system:                 
 The residence time of the drug delivery device in the stomach can also be 
sustained by incorporation of an inflatable chamber, which contains a liquid, e.g., ether 
that gasifies at body temperature to cause the chamber to float in the stomach. 
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             Figure 1.9 Inflatable gastrointestinal drug delivery device 
 
c. Intragastric osmotically controlled drug delivery system:              
 It is comprised of an osmotic pressure controlled drug delivery and an inflatable 
floating support in a bio-erodible capsule. When the drug delivery device reaches the site 
of drug administration e.g. the stomach, the capsule quickly disintegrates to release the 
intragastric osmotically controlled drug delivery device. The inflatable floating support is 
made from a deformable hollow polymeric bag that contains a liquid that gasifies at body 
temperature to inflate the bag. Although single unit floating dosage forms have been 
extensively studied, these single unit dosage forms have the disadvantage of a release all 
or nothing emptying process while the multiple unit particulate system pass through the 
GIT to avoid the vagaries of gastric emptying and thus, release the drug more uniformly. 
 The uniform distribution of these multiple unit dosage forms along the GIT could result 
in more reproducible drug absorption and reduced risk of local irritation; this gave birth 
to oral controlled drug delivery and led to development of gastro-retentive floating 
microspheres. 
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             Figure 1.10 Intragasric osmotically controlled drug delivery device. 
 
B.   Non-Effervescent FDDS 
                Floating microsphere are gastro-retentive delivery systems based on non-
effervescent approach.  Gastro-retentive floating microspheres are low density systems 
that have sufficient buoyancy to float over gastric contents and remain in stomach for 
prolonged period.  As the system floats over gastric contents, the drug is released slowly 
at desired rate resulting increased gastric retention with reduced fluctuations in plasma 
drug concentration.  Hollow microspheres are prepared by solvent diffusion and 
evaporation methods to create the hollow inner core.   
a. Hydro dynamically balanced intragastric delivery system  
The hydro dynamically balanced gastrointestinal drug delivery systems, in either 
capsule or tablet form, is designed to prolong GI residence time in an area of the GI tract 
to maximize drug reaching its absorption site in solution state and hence, ready for 
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absorption. It is prepared by incorporating a high level (20-75% w/w) of one or more gel-
forming hydrocolloids e.g. hydroxyl ethylcellulose, hydroxypropyl cellulose, hydroxyl 
propyl methyl cellulose and sodium carboxy methyl cellulose into the formulation and 
then compressing these granules into a tablets.  
On contact with gastric fluid the hydrocolloid in this intragatric floating device 
start to become hydrated and forms a colloid gel barrier around its surface with thickness 
growing with time. This barrier controls the rate of solvent penetration into the device 
and the rate of drug release from the device (Figure 1.11). It maintains a bulk density of 
less than 1 and thus, remains buoyant in the gastric fluid inside the stomach for up to 6 
hours.  
 
Figure 1.11 Working principle of hydrodynamically balance system 
 
b. Bilayer tablet:                    
 A bilayer tablet can be prepared to contain one immediate–release layer and one 
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sustained–release layer. After the initial dose is delivered by the immediate release layer, 
the sustained layer absorbs the gastric fluid and forms a colloidal gel barrier on its 
surface.  This produces a bulk density less than that of the gastric fluid and release 
remains buoyant in the stomach for extended period of time.  
   
 
 
 
 
 
 
 
Figure 1.12 Intragastric floating bilayer tablet 
 
c. Intragastric floating gastrointestinal drug delivery system: 
               A gastrointestinal drug delivery system can be made to float in the stomach by 
incorporating a floatation chamber, which may be a vacuum or filled with a harmless gas. 
 
 
 
        
               
                 Figure 1.13 Intra-gastric floating drug delivery device 
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 A drug reservoir is encapsulated inside a micro-porous compartment with 
apertures along its top and bottom walls. The peripheral walls of the drug reservoir 
compartment are completely sealed to prevent any direct contact of the stomach mucosal 
surface with the un-dissolved drug. In the stomach the floatation chamber causes the 
gastrointestinal drug delivery system to float in the gastric fluids. Fluids enter through the 
apertures, dissolve the drug and carry and drug solute out of the drug delivery system for 
continuous transport to the intestine for absorption. The other two walls in contact with 
the fluid are sealed so that undissolved drug remains therein. 
 
1.8 LIMITATIONS OF FDDS (Mayavanshi A.V. and Gajjar S.S., 2008) 
 The major limitation of floating system is requirement of a sufficient high level of 
fluids in the stomach for the drug delivery to float. However this limitation can be 
overcome by coating the dosage form with the help of bio-adhesive polymers that 
easily adhere to the mucosal lining of the stomach. 
 Floating system is not feasible for those drugs that have solubility or stability 
problem in gastric fluids.  
  Drugs which are irritant to gastric mucosa cannot be applicable to GRDFs, 
floating system.  
 The residence time in the stomach depends upon the digestive state. Hence FDDS 
should be administered after the meal. 
 The ability of drug to remain in the stomach depends upon the subject being 
positioned upright.  
 The dosage form should be administered with a minimum of glass full of water 
(250 ml). 
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1.9 ADVANTAGES OF FDDS (Garg R. and Gupta G.D., 2008; Mayavanshi A.V, 
Gajjar S.S.2008) 
 It is advantageous for drugs absorbed through the stomach, for e.g. Riboflavin. 
 It is not restricted to medicaments, which are absorbed from stomach, since it has 
been found that these are equally efficacious with medicaments which are 
absorbed from the intestine.  
 It is advantageous for drugs meant for local action in the stomach, for e.g. 
antacids, antiulcer drugs. 
 It reduces fluctuations in circulating blood level of drug as shown by the 
conventional dosage form. 
 It shows more uniform levels of drug in plasma. 
 It releases drug slowly and for prolonged period of time and hence reduces dosing 
frequency.  
 It increases patient compliance as the dosing frequency is reduced.  
 The dissolved drug gets available for absorption in the small intestine after 
emptying of the stomach contents. It is therefore expected that a drug will be fully 
absorbed from the floating dosage forms if it remains in the solution. 
 Site specific drug delivery. 
 Retention of the drug in the GRDF at the stomach minimizes the amount of drug 
that reaches the colon, hence minimizes adverse activity at the colon.  
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1.10  APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEMS  
(Bandyopadhyay A.K., 2008; Mayavanshi A.V, Gajjar S.S.,2008) 
 Floating drug delivery offers several applications for drugs having poor 
bioavailability because of the narrow absorption window in the upper part of the 
gastrointestinal tract.  
 Sustained Drug Delivery 
HBS systems can remain in the stomach for long periods and hence can release the 
drug over a prolonged period of time. The problem of short gastric residence time 
encountered with an oral CR formulation hence can be overcome with these systems. 
These systems have a bulk density of 1 as a result of which they can float on the gastric 
contents.  
The sustained release floating capsules of nicardipine hydrochloride compared with 
commercially available MICARD capsules using rabbits. Plasma concentration time 
curves showed a longer duration for administration (16 hours) in the sustained release 
floating capsules as compared with conventional MICARD capsules (8 hours).  
 
 Site-Specific Drug Delivery 
These systems are particularly advantageous for drugs that are specifically absorbed 
from stomach or the proximal part of the small intestine, eg, furosemide.  
It has been reported that a monolithic floating dosage form with prolonged gastric 
residence time was developed and the bioavailability was increased. AUC obtained with 
the floating tablets was approximately 1.8 times those of conventional furosemide tablets.  
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 Absorption Enhancement 
Drugs that have poor bioavailability because of site specific absorption from the 
upper part of the gastrointestinal tract are potential candidates to be formulated as 
floating drug delivery systems, thereby maximizing their absorption.  
 
1.11 MICROSPHERES (shobharani., 2008; Kedar Prasad Meena and Danji J.S., et al., 
2011) 
 Microspheres are solid, approximately spherical particles ranging 1-1000µm in 
size. They are made up of polymeric substances, in which the drug is dispersed 
throughout the microsphere matrix. The substances used in the formulation are 
biodegradable synthetic polymers and natural products. The natural polymers of choice 
are albumin and gelatin, the synthetic ones being polylactic acid and polyglycolic acid. 
The polymers used to manufacture microspheres are chosen according to their solubility, 
stability profile, process, safety and economic suitability. 
 
Figure 1.14 Microsphere 
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Prerequisites for ideal micosphere carriers: 
            The polymer utilized for the preparation of microspheres should ideally fulfill the 
following prerequisites: 
 Longer duration of action 
 Control of content release 
 Increase of therapeutic efficacy 
 Protection of drug 
 Reduction of toxicity 
 Biocompatibility 
 Sterilizability 
 Relative stability 
 Water solubility or dispersability 
 Bioresorbability 
 Targetability 
 Polyvalent 
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2. AIM AND OBJECTIVE 
 
Aim: 
Oral floating drug delivery system is a suitable drug delivery approach for the 
drug having low and varied bioavailability e.g. Celecoxib (COX-2 inhibitor) has lesser 
oral bioavailability and poor absorption in large intestine and poor physicochemical 
properties like wetting and solubility (Class-II drug according to BCS classification 
system). Bioavailability of Celecoxib is only 30% when given orally in capsules. The 
gastro retentive floating microparticulates of Celecoxib would retain the drug in stomach 
and continuously release the drug in a controlled manner in a predetermined time 
proposed leading to improved bioavailability. The selection of polymer which is able to 
release the drug in controlled fashion with initial burst, release of drug to initial 
therapeutic level quickly.  
 
 Floating sustained release delivery systems for oral dosing are effective in 
achieving optimal therapy with drugs that have a narrow therapeutic range of 
blood concentration which eliminate rapidly.  
  One of the methods of fabricating sustained release formulations in incorporation 
of the drug in the floating matrix containing a hydrophilic rate controlling 
polymer.  
 The FDDS is able to prolong the retention time of a dosage form in the stomach, 
thereby improving the oral bioavailability of the drug.  
 These microparticulates are prepared using solvent diffusion and evaporation 
technique.  
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Objectives: 
 To reduce dosing frequency and improve patient compliance. 
 Formulate and evaluate the non-effervescent floating microparticulates of 
Celecoxib using different synthetic polymers viz. Hydroxy Propyl Methyl 
Cellulose (HPMC K15M) and Ethyl Cellulose. 
 To optimize the concentration of drug-polymer ratio for suitable formulation. 
 To characterize the microsphere for its physiochemical properties. 
 To evaluate the microsphere for surface characterization with SEM and drug-
polymer compatibility study with DSC and FTIR. 
 To determine the Buoyancy, Drug Content Uniformity, Drug entrapment 
efficiency, in-vitro drug release studies of microparticulates. 
 In-vitro drug release kinetic study for release mechanism by the best fit model.  
 To determine the Ex-vivo permeation studies for best formulation. 
 To perform stability studies for best formulation. 
    
 
 
 
 
 
 
 
 
 
 
PLAN OF WORK
 Non-effervescent floating microparticulates of Celecoxib Plan of work 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 37 
3. PLAN OF WORK 
 
 LITERATURE REVIEW 
 SELECTION OF DRUG AND POLYMER 
 PROCUREMENT OF DRUG AND EXCIPIENTS 
 EXPERIMENTAL WORK 
a)  PREFORMULATION STUDIES 
 Identification of drug 
 By FTIR spectroscopy 
 By melting point 
 Physicochemical parameters 
 Organoleptic properties 
 Solubility profile 
 Loss on drying 
 Analytical methods 
 Determination of λ max 
 Development of standard curve of Celecoxib 
 Determination of percentage purity of drug 
 Determination of compatibility for drug with polymer 
 By DSC thermal analysis  
 By FTIR Spectroscopy 
b)  PREPARATION OF NON-EFFERVESCENT FLOATING 
MICROPARTICULATES 
 By solvent diffusion and evaporation method 
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c)  EVALUATION OF NON-EFFERVESCENT FLOATING 
MICROPARTICULATES 
 Appearance 
 Percentage Yield 
 Micromeritics properties of Non-effervescent floating microparticulates 
 Bulk Density 
 Tapped Density 
 Carr’s Compressibility Index 
 Hausner’s Ratio 
 Angle of Repose 
 Particle size distribution 
 Loss on Drying 
 Buoyancy Test 
 Entrapment efficiency 
 Characterization of microparticulates 
 By scanning electron microscopy 
 In-vitro Drug release studies 
 Kinetics of In-vitro drug release 
 Ex-vivo permeation studies 
 STABILITY STUDIES
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4. REVIEW OF LITERATURE 
 
In recent years scientific and technological advancements have been made in the 
research and development of rate-controlled drug delivery system by overcoming 
physiological adversities such as short gastric residence time (GRT) and unpredictable 
gastric emptying time (GET). Several approaches are currently utilized in the 
prolongation of GRT, including floating drug delivery system (FDDS), also known as 
hydrodynamically balanced system (HBS), swelling and expanding system, polymeric 
bioadhesive system, modified shape system, high density system, and other delayed 
gastric emptying devices. 
 
Literature review indicating advancement in floating drug delivery system is given 
below: 
 
Margret C.R., et al., (2010) had formulated floating tablets of Itopride 
hydrochloride using an effervescent approach for gastroretentive drug delivery system. In 
recent years scientific and technological advancements have been made in the research 
and development of controlled release oral drug delivery systems by overcoming 
physiological adversities like short gastric residence times and unpredictable gastric 
emptying times. The present investigation concerns the development of floating tablets of 
Itopride hydrochloride, a novel prokinetic drug, which after oral administration are 
designed to prolong the gastric residence time and thereby increase drug bioavailability, 
and drug release rate. Floating tablets were fabricated; using direct compression method; 
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containing Itopride hydrochloride, polymers HPMC K100M, HPMC K15M and 
Carbopol 934P. 
 
Vishal G.K., et al., (2010) had prepared a Floating tablet of Furosemide (FUR) 
by direct compression technique. Furosemide was chosen as model drug because it is 
slightly soluble in water and poorly absorb from lower intestine. PEG-6000 is used as 
carrier agent for increasing solubility of Furosemide in water. Hydroxypropyl 
methylcellulose, sodium bicarbonate and carbopol were used as matrixing agent, gas 
generating agent and floating agent respectively. 
 
Dhawale S.C., et al., (2009) had developed and evaluated floating drug delivery 
system of Acyclovir. Gastric floating drug delivery was employed to develop controlled 
release preparation. Sodium bicarbonte as gas generating agent dispersed in a hydrogel 
matrix. The matrix was a mixture of HPMC K4M, HPMC K100M and xanthan gum. 
 
Dalavi V.V., et al., (2009) had developed gastroretentive drug delivery system of 
an antiretroviral agent of Zidovudine to achieve the objective, 3×3 factorial design were 
chosen. In this design amount of HPMC K4M (X1) and gas generating agents (X2) were 
selected as independent variable. The time required for 50% drug release t50% (Y1) was 
selected as dependent variable. The derived polynomial equations for t50%were verified 
by two check point formulations. The results of factorial design showed that factor X1 
and X2 significantly affect the studied dependent variables. The formulation with good 
floating time (24 hrs) and the percent drug release (98.05 %) emerged as optimal. 
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Kishan V., et al., (2009) had developed Floating matrix tablets of Norfloxacin to 
prolong gastric residence time, leading to an increase in drug bioavailability. Tablets 
were prepared by the wet granulation technique, using polymers such as Hydroxy propyl 
methyl cellulose (HPMC-K4M, HPMC-K100M) and Xanthan gum. 
 
Prakash R.C., et al., (2009) had formulated and optimizes the floating drug 
delivery systems containing cephalexin using 23 factorial design. Floating tablets were 
prepared by direct compression method incorporating HPMC K4M, Xanthan Gum, Guar 
Gum, Sodium bicarbonate and tartaric acid as a gas generating agent. The influences of 
independent variables like polymer polymer ratio polymer type on floating lag time and 
cephalaxin release profiles were studied. 
 
Kshirsagar R.V., et al., (2009) had developed a hydro dynamically balanced 
system of metformin as a single unit floating tablet. Various grades of low‐density 
polymers were used for the formulation of this system. They were prepared by physical 
blending of metformin and the polymers in varying ratios. The formulation was 
optimized on the basis of in-vitro buoyancy and in-vitro release in simulated gastric fluid 
pH 1.2. Effect of Carbopol as a release modifier was studied to ensure the delivery of 
drug from the floating tables over a prolonged time period. Tablets prepared with HPMC 
K15M and Carbopol gave the best in-vitro percentage release and were taken as the 
optimized formulation. 
 
 Non-effervescent floating microparticulates of Celecoxib Review of Literature 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 43 
Rajesh K., et al., (2009) had been prepared ranitidine hydrochloride sustained 
release formulation for 24 hrs. Various formulations were prepared by wet granulation 
technique using the polymers, such as HPMC K100M and HPMC K15M. It was found 
that the best formulation for RT8 was having the floating lag time of 120 sec and showed 
98.4% drug release at the end of 24 hours. In-vitro drug release studies of Ranitidine 
hydrochloride sustained release floating tablets showed that, the rate of drug release is 
diffusion controlled and follows zero order kinetics. 
 
Sauzet C., et al., (2009) had formulated different technologies intended for gastro 
retentive dosage delivery were investigated and patented. The aim of this study was to 
develop an innovative floating gastro retentive dosage form (GRDF). The developed 
technology induces a low-density dosage form containing high active pharmaceutical 
ingredient (API) concentration by using a hydrophobic dusty powder excipient under 
specific conditions. The new dosage form was obtained by state of the art wet granulation 
manufacturing process. An apparatus was developed to measure the apparent density of 
floating tablet. The GRDF was characterized for apparent density, buoyancy, porosity 
and dissolution using in-vitro experimentations. 
 
Anand P., et al., (2009) had developed a novel gastro retentive controlled release 
drug delivery system of verapamil HCl was formulated in an effort to increase the gastric 
retention time of the dosage form and to control drug release. Hydroxy propyl methyl 
cellulose (HPMC), carbopol, and xanthan gum were incorporated for gel forming 
properties. Buoyancy achieved by adding an effervescent mixture of sodium bicarbonate 
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and anhydrous citric acid. In-vitro drug release studies were performed, and drug release 
kinetics was evaluated using the linear regression method. 
 
Ajit K., et al., (2009) design bilayer regioselective floating tablets of Atenolol 
and Lovastatin to give immediate release of Lovastatin and sustained release of Atenolol. 
Bilayer floating tablets comprised two layers, i.e immediate release and controlled release 
layers. The immediate release layer comprised sodium starch glycollate as a super 
disintegrant and the sustained release layer comprised HPMC K100M and xanthan gum 
as the release retarding polymers. Sodium bicarbonate was used as a gas generating 
agent. Direct compression method was used for formulation of the bilayer tablets. 
Accelerated stability studies were carried out on the prepared tablets in accordance with 
ICH guidelines. All formulations floated for more than 12 hrs. More than 90% of 
Lovastatin was released within 30 min. Diffusion exponents (n) were determined for all 
the formulations (0.53-0.59). The release of Atenolol was found to follow a mixed pattern 
of Korsmeyer-Peppas, Hixson- Crowell and zero order release models. The optimized 
formulation was found to be buoyant for 8 hrs in stomach. Therefore, biphasic drug 
release pattern was successfully achieved through the formulation of floating bilayer 
tablets in this study. 
 
Prajapati S.T., et al., (2009) developed gastric floating matrix tablet of 
Domperidone. Box-Behnken design was employed in formulating gastric floating drug 
delivery system using three polymers HPMC (K4M), Carbopol 934P, Sodium alginate as 
independent variables. HPMC loading was found to be significant for floating properties. 
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No significant effect of Sodium alginate on floating properties was observed but it was 
important for gel formation. The quadratic mathematical model developed could be used 
to predict formulations with desired release and floating properties. 
   
Thakkar V.T., et al., (2008) had developed and evaluates the Levofloxacin 
hemihydrates floating formulations (F1-F9). Selection of optimized batch was done by 
model dependent approach and novel mathematical approach. F1-F9 batches were 
prepared by direct compression method using Gelucire 43/01 (hydrophobic) and hydroxy 
propyl methyl cellulose (hydrophilic) polymer in different ratios. The floating tablets 
were evaluated for uniformity of weight, hardness, friability, drug content, in-vitro 
buoyancy and in-vitro release studies. Various models were used to estimate kinetics of 
drug release. 
 
Jaimini M., et al., (2007) had formulated and evaluated floating tablets of 
Famotidine which were prepared by effervescent approach using two different grades of 
Methocel K100 and K15M. The tablets with Methocel K100 were found to float for 
longer duration as compared with formulations containing Methocel K15M. The drug 
release from the tablets was sufficiently sustained and non-Fickian transport of the drug 
from tablets was confirmed. 
 
Shishu N., et al., (2007) 5-Fluorouracil (5-FU) has been the most widely used 
drug for the chemotherapy of gastrointestinal cancer for many decades. The present 
investigation concerns the development and evaluation of single unit floating tablets of 5-
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FU which, after oral administration, are designed to prolong the gastric residence time, 
increase drug bioavailability and target the stomach cancer. A floating drug delivery 
system (FDDS) was developed using gas-forming agents, like sodium bicarbonate, citric 
acid and hydrocolloids, like hydroxyl propyl methyl cellulose (HPMC) and Carbopol 
934P. The formulations were optimized for the type of filler, like lactose, 
microcrystalline cellulose (MCC) and dicalcium phosphate (DCP) as well; different 
viscosity grades of HPMC and concentrations. 
 
Sanjay S.P., et al., (2006) had developed floating matrix tablets are designed to 
prolong the gastric residence time after oral administration, at a particular site and 
controlling the release of drug especially useful for achieving controlled plasma level as 
well as improving bioavailability. With this objective, floating dosage form containing 
clarithromycin as drug was designed for the treatment of Helicobacter pylori. 
Incorporation of gas-generating agent together with polymer improved drug release, 
besides optimal floating (floating lag time <30 s; total floating time >10 h). 
 
Patel V.F, et al., (2006) developed intragastric floating drug delivery system of 
Cefuroxime axetil and carried out its in-vitro evaluation and employed 32 full factorial 
designs to evaluate contribution of HPMC and SLS on drug release. Tablets were 
prepared using direct compression technique. Multiple regression analysis was performed 
for factorial design batches to evaluate the response. All formulations had floating lag 
times below 2 minutes and constantly floated on dissolution medium for more than 8 
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hours. Also linear relationships were obtained between the amount of HPMC K100 LV 
and diffusion exponent as well as release rate constant. 
 
Dave B.S., et al., (2004) had prepared a floating tablet of Ranitidine 
hydrochloride by using guar gum, xanthan gum and hydroxylpropyl methylcellulose, 
Sodium bicarbonate was incorporated as gasgenerating agent. It is prepared by direct 
compression method and in-vitro study done into 0.1 N HCl as dissolution medium. Drug 
release was calculated by Higuchi and Peppas models. 
 
Hoffman A., et al., (2003) Expandable gastroretentive dosage forms (GRDFs) 
have been designed for the past 3 decades. They were originally created for possible 
veterinary use, but later the design was modified for enhanced drug therapy in humans. 
These GRDFs are easily swallowed and reach a significantly larger size in the stomach 
due to swelling or unfolding processes that prolong their gastric retention time (GRT). 
Positive results were obtained in preclinical and clinical studies evaluating GRT of 
expandable GRDFs. 
 
Kim H. K., et al., (2000) has studied the scientific and technological 
advancements have been made in the research and development of rate-controlled oral 
drug delivery systems by overcoming physiological adversities, such as short gastric 
residence times (GRT) and unpredictable gastric emptying times (GET). Several  
approaches are currently utilized in the prolongation of the GRT, including floating drug 
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delivery systems (FDDS), also known as hydrodynamically balanced systems (HBS), 
swelling and expanding systems, polymeric bioadhesive systems. 
 
Baumgartner S., et al., (2000) had developed a matrix-floating tablet 
incorporating high dose of freely soluble drug. The formulation containing 54.7% of 
drug, HPMC K4 M, Avicel PH 101 and a gas-generating agent had given the best results. 
It required 30 seconds to become buoyant. In-vivo experiments with fasted state in beagle 
dogs revealed prolonged gastric residence time. On radiographic images taken after 30 
minutes of administration, the tablet was observed in animal stomach and the next image 
taken at 1 hr showed that the tablet had altered its position and turned around. The 
comparison of gastric motility and stomach emptying between humans and dogs showed 
no big difference hence it was speculated that the experimentally proven increased gastric 
residence time in dogs than humans. 
 
Literature review indicating work carried out on selected drug, Celecoxib is given 
below: 
 
Satish Singh, et al., (2012) has been formulated non effervescent gastroretentive 
floating drug delivery of Celecoxib to increase therapeutic efficacy, reduce frequency of 
administration and improve patient compliance. Solvent evaporation was used to prepare 
the microparticulates and evaluated for buoyancy, density, particle size, SEM, in-vitro 
dissolution, in-vitro permeation and in-vivo studies. Polymers Ethyl Cellulose, Dibutyl 
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Phthalate and Methocel were used. In-vitro drug release was performed for 8 hours and 
the percentage drug release was found to be 52.58% to 61.57% 
 
Punitha, et al, (2009) has studied to improve the physicochemical properties of 
celecoxib like solubility, dissolution properties and stability of poorly soluble drug by 
forming dispersion with urea as water soluble carrier. The solid dispersion of celecoxib 
by physical triturating method, Solvent evaporation and fusion method were prepared 
using 1:1, 1:3 and 1:5 ratios of drug and polymer (urea). The saturation solubility was 
carried using USP type XXIV (paddle) type dissolution apparatus. The prepared 
dispersion showed marked increase in the saturation solubility and dissolution rate of 
celecoxib than that of pure drug. The dispersion with urea (1:5) by fusion method showed 
faster dissolution rate (79.08%) as compared to other dispersions with urea (1:1 and 1:3) 
whichever prepared by physical mixture and solvent evaporation method.  Solid 
dispersion of celecoxib: urea prepared as 1:5 ratio by fusion method showed excellent 
physicochemical characteristics and was found to be described by dissolution release 
kinetics and was selected as the best formulation in this study. 
 
Karade Preeti, et al (2012) has developed  a topical gel formulation of celecoxib, 
which would attenuate the gastrointestinal relater toxicities associated with oral 
administration and to investigate the effect of DMSO on permeation of celecoxib. Gel 
with different concentrations of carbapol, sodium alginate and sodium carboxy 
methylcellulose were prepared. Gels were subjected for various evaluation tests such as 
pH measurement, spreadibility and extrudability. In-vitro dissolution studies were 
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performed in phosphate buffer of pH 5.6 and polyethylene glycol 400 (7.4 pH) for 12 hrs 
by using Keshary-Chien diffusion cell apparatus. The gel formulation consisting of 7.5% 
w/w sodium alginate with DMSO found to be suitable for topical application based on in-
vitro evaluation. Sodium alginate based gels with DMSO revealed of 90% cumulative 
drug release after 12 hours. From the above observations, Sodium alginate seems to be a 
promising pharmaceutical adjuvant in the formulation of celecoxib gels. 
 
Mohammed Mostafa Ibrahim, et al., (2013), Celecoxib-loaded NPs were 
prepared from biodegradable polymers such as poly-caprolactone (PCL), poly(L-lactide) 
(PLA), and poly(D,L-lactide-co-glycolide) by spontaneous emulsification solvent 
diffusion method. Nanoparticles (NPs) were characterized regarding their particle size, 
PDI, zeta potential, shape, morphology, and drug content. Celecoxib-loaded NPs were 
incorporated into eye drops, in situ gelling system, and gel and characterized regarding 
their pH, viscosity, uniformity of drug content, in-vitro release, and cytotoxicity. 
 
Shahzad, et al., (2012), employed response surface methodology (RSM) for 
statistical optimization of formulation factors in the preparation of celecoxib-loaded 
microspheres. Celecoxib microspheres were prepared by solvent evaporation method.  
Biodegradable/biocompatible polymers, Eudragit L-100 and polyvinyl pyrrolidone, were 
used in the encapsulation procedure. The microspheres were characterized for size, shape, 
recovery (%), entrapment efficiency and drug release. Using RSM, Celecoxib-loaded 
microsphere formulation with optimum recovery, entrapment efficiency and release 
behavior was proposed. 
  
 
 
 
 
 
 
 
DRUG AND 
EXCIPIENTS 
PROFILE
 Non-effervescent floating microparticulates of Celecoxib Drug & Excipients Profile 
 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 52 
 
5. DRUG AND EXCIPIENTS PROFILE 
 
5.1. DRUG PROFILE: 
CELECOXIB: (USP, 2012; http://www.drugbank.ca/drugs/DB00482) 
Celecoxib is a Non-Steroidal anti-inflammatory drug (NSAID). This drugs is still 
among the most widely used drugs in the world. Celecoxib is used in the treatment of 
pain and inflammation, associated with rheumatoid arthritis, and several other 
inflammatory disorders. Celecoxib is a COX-2 specific inhibitor, promoting a reduction 
of the inflammatory process and maintaining normal physiological levels of prostanoids 
in stomach and kidneys. It appears to have a gastrointestinal safety profile superior to the 
traditional NSAID. 
 
A. IUPAC Name: 4-[5- (4- methyl phenyl) - 3- (trifluoro methyl) - 1H-pyrazol- 1-yl] 
benzene sulfonamide 
 
B. Molecular Structure: 
 
Figure 5.1 Molecular structure of Celecoxib 
 
C. Category: Non-Steroidal Anti-Inflammatory Drug (NSAID). 
 First specific inhibitor of cyclo-oxygenase-2 (COX-2) 
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D. Molecular formula: C17H14F3N7O2S 
 
E. Molecular weight: 381.37 
 
F. Description: White or almost white, crystalline or amorphous powder. 
 
G. Solubility: Soluble to freely soluble in ethanol; soluble in Methylene chloride; 
practically insoluble in water. 
 
H. Melting Range: 161.3°C to 162.2°C 
 
I. Peak Plasma concentration: 3 hours 
 
J. Recommended daily Dose: 200 mg taken once daily or in two divided doses. 
 
K. Pharmacokinetics: 
 
Figure 5.2 Hepatic metabolism of Celecoxib 
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After oral administration, Celecoxib is rapidly absorbed and achieves peak serum 
concentration in about 3 hours. It is extensively metabolized in the liver with very little 
drug (<3 %) being eliminated unchanged. The major routes of excretion for Celecoxib are 
feces and urine. Celecoxib is metabolized primarily through methyl hydroxylation to 
form hydroxycelecoxib. This reaction is largely catalyzed by CYP2C9, although 
CYP3A4 also plays a minor (<25 %) role. Hydroxy-celecoxib is further oxidized to form 
carboxy-celecoxib via cytosolic alcohol dehydrogenases ADH1 and ADH2, then 
conjugated with glucuronic acid via UDP glucuronosyl transferases (UGT’s) to form the 
1-O-glucuronide. None of the metabolites are pharmacologically active. 
 
L. PHARMACOKINETICS  DATA: 
 Bioavailability: approx 43%  
 Apparent volume of distribution: 455±166 Liters 
 Half-life: 11 hours 
 Metabolism: Celecoxib is metabolized in liver.  Celecoxib metabolism is 
primarily mediated vis cytochrome P450 2C9. Three metabolites, a primary 
alcohol, the corresponding carboxylic acid and its glucoronide conjugate,have 
been identified in human plasma. These metabolites are inactive as COX-1 or 
COX-2 inhibitors in in-vitro models.  
 Excretion: Feces and Urine. Celecoxib is eliminated predominantly by hepatic 
metabolism with little (<3 %) unchanged drug recovered in the urine and feces. 
 Plasma protein binding: Highly Plasma protein bound (approx 97 %)  
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M. Pharmacodynamics:  
 Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a non-
steroidal anti-inflammatory drug (NSAID). Celecoxib is used to treat rheumatoid arthritis, 
osteoarthritis, and familial adenomatous polyposis (FAP). Because of its lack of platelet 
effects, Celecoxib is not a substitute for aspirin for cardiovascular prophylaxis. It is not 
known if there are any effects of Celecoxib on platelets that may contribute to the 
increased risk of serious cardiovascular thrombotic adverse events associated with the use 
of Celecoxib. Inhibition of PG-E2 synthesis may lead to sodium and water retention 
through increased reabsorption in the renal medullary thick ascending loop of Henle and 
perhaps other segments of the distal nephron. In the collecting ducts, PG-E2 appears to 
inhibit water reabsorption by counteracting the action of antidiuretic hormone.  
 
N. Mechanism of action:  
 The mechanism of action of celecoxib is believed to be due to inhibition of 
prostaglandin synthesis. Unlike most NSAID’s, which inhibit both types of cyclo-
oxygenases (COX-1 and COX-2), Celecoxib is a selective noncompetitive inhibitor of 
cyclooxygenase-2 (COX-2) enzyme. It binds with its polar sulfonamide side chain to a 
hydrophilic side pocket region close to the active COX-2 binding site. Both COX-1 and 
COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the 
precursor of PGs and thromboxane. 
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O. Indications:  
 Osteoarthritis  Acute pain 
 Rheumatoid Arthritis  Primary Dysmenorrhea 
 Ankylosing Spondylitis  Adenomatous Polyposis 
 
P. Adverse effects: 
Symptoms of overdose include breathing difficulties, coma, drowsiness, 
gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, 
stomach pain, and vomiting. 
 
Q. Drug interactions: 
 Celecoxib may increase the anticoagulant effect of acenocoumarol, anisindione 
and dicumarol. 
 Fluconazole may increase the effect of celecoxib. 
 Bile acid sequestrants may decrease the absorption of Nonsteroidal Anti-
Inflammatory Agents. 
 The COX-2 inhibitor increases serum levels of lithium. 
 Concomitant use of Telmisartan and Celecoxib may increase the risk of acute 
renal failure and hyperkalemia. 
 Celecoxib, may reduce the antihypertensive effect of Trandolapril. 
 Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and 
clearance of Celecoxib. 
 
R. Dosage forms 
 Capsules: 50mg, 100mg, 200mg and 400mg 
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5.2 EXCIPIENTS PROFILE 
 
HYPROMELLOSE (Hydroxy Propyl Methyl Cellulose) (Rowe R.C., et al., 2003) 
A. Nonproprietary Names:  
BP: Hypromellose JP: Hydroxypropylmethylcellulose 
PhEur: Hypromellosum USP: Hypromellose 
 
B. Synonyms: 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
Tylopur. 
 
C. Chemical Name and CAS Registry Number: 
Cellulose hydroxyl propyl methyl ether [9004-65-3] 
 
D. Molecular Weight: 
Molecular weight is approximately 10,000 to 1,500,000. 
 
E. Structural Formula: 
 
Figure 5.3 Structural formula of Hypromellose 
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F. Functional Category: 
Coating agent, Film-former, Rate-controlling polymer for sustained release, Stabilizing 
agent, Suspending agent, Tablet binder, Viscosity-increasing agent. 
 
G. Applications in Pharmaceutical Formulation or Technology: 
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. In oral products, Hypromellose is primarily used as a tablet binder, in film-
coating, and as matrix for use in extended-release tablet formulations. High viscosity 
grades may be used to retard the release of drugs from a matrix at levels of 10–80% w/w 
in tablets and capsules. Lower-viscosity grades are used in aqueous film-coating 
solutions, while higher-viscosity grades are used with organic solvents. 
 
H. Description: 
Hypromellose is an odorless and tasteless, white or creamy-white fibrous or granular 
powder. 
 
I. Typical Properties: 
 Acidity/alkalinity : pH = 5.5–8.0 for a 1% w/w aqueous solution. 
 Density (bulk) : 0.341 g/cm3 
 Density (tapped) : 0.557 g/cm3 
 Density (true)  : 1.326 g/cm3 
 Melting point  : browns at 190–200°C; chars at 225–230°C. 
 Glass transition temperature: 170–180°C. 
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 Moisture content: Hypromellose absorbs moisture from the atmosphere; the amount 
of water absorbed depends upon the initial moisture content and the temperature and 
relative humidity of the surrounding air. 
 Solubility: Soluble in cold water, forming a viscous colloidal solution. Practically 
insoluble in chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol 
and dichloromethane, mixtures of methanol and dichloromethane, and mixtures of 
water and alcohol. 
 Viscosity (dynamic): A wide range of viscosity types are commercially available.  
Table 5.1 Typical viscosity values for 2% w/v aqueous solutions of Methocel at 20°C. 
Methocel product USP 28 designation Nominal viscosity (mPa s) 
Methocel K100 Premium LVEP 2208 100 
Methocel K4M Premium 2208 4000 
Methocel K15M Premium 2208 15 000 
Methocel K100M Premium 2208 100 000 
Methocel E4M Premium 2910 4000 
Methocel F50 Premium 2906 50 
Methocel E10M Premium CR 2906 10 000 
Methocel E3 Premium LV 2906 3 
Methocel E5 Premium LV 2906 5 
Methocel E6 Premium LV 2906 6 
Methocel E15 Premium LV 2906 15 
Metolose 60SH 2910 50, 4000, 10 000 
Metolose 65SH 2906 50, 400, 1500, 4000 
Metolose 90SH 2208 100, 400, 4000, 15 000 
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Aqueous solutions are most commonly prepared, although Hypromellose may also be 
dissolved in aqueous alcohols such as ethanol and propan-2-ol provided the alcohol 
content is less than 50% w/w. 
 
J. Stability and Storage Conditions 
Hypromellose powder is a stable material, although it is hygroscopic after drying. 
Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions. 
Hypromellose undergoes a reversible sol–gel transformation upon heating and cooling, 
respectively. 
 
K. Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts. 
 
ETHYL CELLULOSE: (Rowe R.C., et al., 2003; http://www.ethocel.com ) 
A. Nonproprietary Names: 
BP: Ethyl cellulose USP-NF:  Ethyl cellulose 
PhEur: Ethylcellulosum  
 
B. Synonyms: 
Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
 
C. Chemical Name and CAS Registry Number: 
Cellulose ethyl ether [9004-57-3]. 
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D. Structural Formula: 
 
Figure 5.4 Structural formula of Ethyl cellulose 
 
E. Functional Category: 
Coating agent, Flavoring fixative, Tablet binder, Tablet filler, Viscosity-increasing agent. 
 
F. Applications in Pharmaceutical Formulation or Technology:  
Ethyl cellulose is a derivative of cellulose in which some of the hydroxyl groups on the 
repeating glucose units are converted into ethyl ether groups.  
Table 5.2: Use of Ethyl cellulose depending on concentration 
Use Concentration (%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
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The number of ethyl groups can vary depending on the manufacturer. It is widely used as 
a thin-film coating material. It is also used as a food additive as an emulsifier. Ethyl 
cellulose is widely used in oral and topical pharmaceutical formulations. 
 
G. Description: 
Ethyl cellulose is an odorless and tasteless, white powder. 
 
H. Typical Properties: 
 Density (bulk)   : 0.4 g/cm3 
 Melting point    : 165 - 173°C. 
 Glass transition temperature : 129–133°C. 
 Specific gravity   : 1.12–1.15 g/cm3 
 Moisture content: Ethyl cellulose absorbs very little water from humid air or 
during immersion, and that small amount evaporates readily. 
 Solubility: Ethyl cellulose is practically insoluble in glycerin, propylene glycol, and 
water. Ethyl cellulose that contains less than 46.5% of ethoxyl groups is freely 
soluble in chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of 
aromatic hydrocarbons with ethanol (95%). Ethyl cellulose that contains not less 
than 46.5% of ethoxyl groups is freely soluble in chloroform, ethanol (95%), ethyl 
acetate, methanol, and toluene.  
 Viscosity: Viscosity of ethyl cellulose is measured typically at 25°C using 5% w/v 
ethyl cellulose dissolved in a solvent blend of 80% toluene: 20% ethanol (w/w). 
Grades of ethyl cellulose with various viscosities are commercially available. They 
may be used to produce 5% w/v solutions in organic solvent blends with viscosities 
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nominally ranging from 7 to 100 mPa s (7–100 cP). Specific ethyl cellulose grades, 
or blends of different grades, may be used to obtain solutions of a desired viscosity. 
Solutions of higher viscosity tend to be composed of longer polymer chains and 
produce strong and durable films. The viscosity of an ethyl cellulose solution 
increases with an increase in ethyl cellulose concentration; e.g. the viscosity of a 
5% w/v solution of Ethocel Standard 4 Premium is 4 mPa s (4 cP) and of a 25% w/v 
solution of the same ethyl cellulose grade is 850 mPa s (850 cP). Solutions with a 
lower viscosity may be obtained by incorporating a higher percentage (30–40%) of 
a low-molecular-weight aliphatic alcohol such as ethanol, butanol, propan-2-ol, or 
n-butanol with toluene. The viscosity of such solutions depends almost entirely on 
the alcohol content and is independent of toluene. In addition, non-pharmaceutical 
grades of ethyl cellulose that differ in their ethoxyl content and degree of 
polymerization are available. 
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6. MATERIALS AND EQUIPMENTS 
 
6.1: Raw materials 
Table 6.1: Raw materials with name of the supplier 
S.No Name of Raw material Name of the supplier 
1 Celecoxib Alembic Limited, Gujarat. 
2 HPMC K15M Griffon laboratories Pvt. Ltd., Mumbai. 
3 Ethyl cellulose Griffon laboratories Pvt. Ltd., Mumbai. 
4 Dichloromethane S.D fine-chem limited, Mumbai. 
5 Dimethyl formamide S.D fine-chem limited, Mumbai. 
6 Liquid paraffin Qualigens fine chemicals, Mumbai. 
7 Tween 80 Qualigens fine chemicals, Mumbai. 
8 Petroleum ether S.D fine-chem limited, Mumbai. 
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6.2: Equipments 
Table 6.2:  Equipments with Make and Model 
S.No Name of the Equipments Make and Model 
1 Electronic balance  Shimadzu BL-220H 
2 Digital pH meter  ELICO-LI120 
3 Mechanical Stirrer  Remi equipments limited,  Mumbai 
4 Magnetic Stirrer  Remi equipments limited,  Mumbai 
5 UV Visible Spectrophotometer  ELICO SL159 
6 USP tablet dissolution apparatus  Veego scientific VDA-8DR 
7 Scanning electron microscope Model-S-3400N, SEM HITACHI 
8 UV visible spectrophotometer 
Shimadzu-1700 Pharmaspec UV visible 
spectrophotometer 
9 FTIR spectrophotometer Shimadzu S4008 
10 Differential scanning calorimeter Shimadzu  DSC 60, Japan 
11 Particle size analyzer 
Malvern Particle size analyzer (Master Seizer 
2000) 
 
  
 
 
 
 
 
 
 
 
 
EXPERIMENTAL 
WORK
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7. EXPERIMENTAL WORK 
 
7.1 Preformulation studies 
Preformulation testing was an investigation of physical and chemical properties of 
a drug substance alone. It was the first step in rational development of dosage form. 
 
7.1.1. Identification of drug 
A] By FTIR spectroscopy (IP, 2007) 
Celecoxib discs were prepared by pressing the Celecoxib with potassium bromide 
and the spectra between 4000
-1 
to 500
-1 
cm was obtained under the operational 
conditions. The absorption maximums in spectrum obtained with the substance being 
examined correspond in position and relative intensity to those in the reference spectrum 
in Table 8.1 and Figure 8.1 
 
B] By melting point (IP, 2007) 
Melting point of the drug was determined by capillary tube method. 
 
7.1.2. Physicochemical parameters 
A] Organoleptic properties (Lachman L., et al., 1991; Bankar G.S. and Rhodes C.T., 
1996) 
The color, odor and nature of the drug were recorded using descriptive terminology. 
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B] Solubility study (Merck Index, IP, 2007) 
It is important to know about solubility characteristic of a drug in aqueous system, 
since they must possess some limited aqueous solubility to elicit a therapeutic response. 
The solubility of   drug   was   recorded   by   using   various   descriptive   terminology   
specified   in   Indian pharmacopoeia, 2007. The solubility study was shown in Table 8.4. 
Table: 7.1. Values for estimating drug solubility based upon ―USP definition‖ 
Descriptive Term Appropriate volume of solvent in milliliters per gram of solute 
Very soluble Less than 1 part solvent needed to dissolve 1 part solute 
Freely soluble From 1 to 10 parts solvent needed to dissolve 1 part solute 
Soluble From 10 to 30 parts solvent needed to dissolve 1 part solute 
Sparingly soluble From 30 to 100 parts solvent needed to dissolve 1 part solute 
Slightly soluble From 100 to 1000 parts solvent needed to dissolve 1 part solute 
Very slightly soluble From 1000 to 10,000 parts solvent needed to dissolve 1 part solute 
Practically insoluble More than 10,000 parts solvent needed to dissolve 1 part solute 
 
 
C] Loss on drying (IP, 2007) 
Loss on drying is the loss of weight expressed as percentage w/w resulting from 
water and volatile matter of any kind that can be driven off under specified condition. 
The accurately weighed  1 gm  of  sample  was  transferred  in stoppered-glass  shallow  
weighing  bottle  and accurately weighed the bottle. The bottle was transferred in oven 
and substance was dried at 105°C for 3 hours. The bottle was removed from oven and 
reweighed. Loss on drying was calculated by following equation. It was shown in Table 
8.5 
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 [Initial Weight of sample taken - Final Weight of sample after drying] 
Loss on Drying = --------------------------------------------------------------------------------------- x 100 
    Initial Weight of sample taken 
 
 
7.1.3. Determination of λ max (Fabián Teixeira Primo., et al., 2005) 
The absorption maximum of the standard solution was scanned between 200-
400 nm regions on UV-VISIBLE spectrophotometer. The absorption maximum 
obtained with the substance being examined corresponds in position and relative 
intensity to those in the reference spectrum. 
 
Preparation of 0.2 N sodium hydroxide: 
Dissolve 8 gm of sodium hydroxide in water and allow to stand and finally 
make up the volume to 1000 ml. 
 
Procedure for determination of λ max using 0.2 N sodium hydroxide: 
50 mg of Celecoxib was weighed accurately and transferred into 50 ml 
volumetric flask and dissolved in 0.2 N NaOH, after dissolution the volume was 
made up to the mark with 0.2 N NaOH (1000 µg/ml). Further dilution was made by 
pipetting 10 ml into  100 ml volumetric flasks  to  acquire  100 µg/ml  solution  made  
up  with  0.2 N NaOH.  Further dilution was made by pipetting 3 ml into 25 ml  
volumetric flasks  to  acquire  12 µg/ ml  solution  made  up  with  0.2 N NaOH.   
 
Preparation of Simulated Gastric Fluid (without Enzyme): 
Dissolve 2 g of Sodium chloride in water. Add 7 mL of Hydrochloric Acid and 
sufficient water to make 1000 mL. 
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Procedure for determination of λ max using Simulated Gastric Fluid (without 
Enzyme): 
50 mg of Celecoxib was weighed accurately and transferred into 50 ml 
volumetric flask and dissolved in 3 ml of methanol, after dissolution the volume was 
made up to the mark with Simulated Gastric Fluid (without Enzyme) (1000 µg/ml). 
Further dilution was made by pipetting 10 ml into 100 ml volumetric flasks to acquire 
100 µg/ml solution made up with Simulated Gastric Fluid (without Enzyme).  Further 
dilution was made by pipetting 3 ml into 25 ml  volumetric flasks  to  acquire  12 µg/ 
ml  solution  made  up  with  Simulated Gastric Fluid (without Enzyme).   
 
7.1.4. Development of standard curve of Celecoxib (Fabián Teixeira Primo., et al., 
2005) 
Standard curve of Celecoxib in 0.2 N Sodium Hydroxide:  
50 mg of Celecoxib was weighed accurately and transferred into 50 ml volumetric 
flask and dissolved in 0.2 N NaOH, after dissolution the volume was made up to the 
mark with 0.2 N NaOH (1000 µg/ml). Further dilution was made by pipetting 10 ml into  
100 ml volumetric flasks  to  acquire  100 µg/ml  solution  made  up  with  0.2 N 
NaOH.  Further dilution was made by pipetting 1, 2, 3, 4 and 5 ml into 25 ml  volumetric 
flasks  to  acquire  4, 8, 12, 16 and 20 µg/ml  solution  made  up  with  0.2 N NaOH.  
The  absorbance measurements of these solutions were carried out against 0.2 N NaOH 
as blank at 252 nm. A calibration curve of Celecoxib was plotted. 
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Standard curve of Celecoxib in Simulated Gastric Fluid (without Enzyme):  
50 mg of Celecoxib was weighed accurately and transferred into 50 ml volumetric 
flask and dissolved in 3 ml of methanol, after dissolution the volume was made up to 
the mark with SGF (without enzyme) (1000 µg/ml). Further dilution was made by 
pipetting 10 ml into 100 ml volumetric flasks to acquire 100 µg/ml solution made up 
with SGF (without enzyme).  Further dilution was made by pipetting 1, 2, 3, 4 and 5 ml 
into 25 ml  volumetric flasks  to  acquire  4, 8, 12, 16 and 20 µg/ml  solution  made  up  
with  SGF (without enzyme).  The absorbance measurements of these solutions were 
carried out against SGF (without enzyme) as blank at 249 nm. A calibration curve of 
Celecoxib was plotted. 
 
7.1.5. Determination of percentage purity of drug: (Fabián Teixeira Primo., et al., 
2005) 
Percentage purity of Celecoxib in 0.2 N Sodium Hydroxide: 
50 mg of Celecoxib was weighed accurately and transferred into 50 ml 
volumetric flask and dissolved in 0.2 N NaOH, after dissolution the volume was 
made up to the mark with 0.2 N NaOH (1000 µg/ml). Further dilution was made by 
pipetting 10 ml into  100 ml volumetric flasks  to  acquire  100 µg/ml  solution  made  
up  with  0.2 N NaOH.  Further dilution was made by pipetting 3 ml into 25 ml  
volumetric flasks  to  acquire  12 µg/ ml  solution  made  up  with  0.2 N NaOH.   
 
Percentage purity of Celecoxib in Simulated Gastric Fluid (without Enzyme): 
50 mg of Celecoxib was weighed accurately and transferred into 50 ml 
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volumetric flask and dissolved in 3ml of methanol, after dissolution the volume was 
made up to the mark with Simulated Gastric Fluid (without Enzyme) (1000 µg/ml). 
Further dilution was made by pipetting 10 ml into  100 ml volumetric flasks  to  
acquire  100 µg/ml  solution  made  up  with  Simulated Gastric Fluid (without 
Enzyme).  Further dilution was made by pipetting 3 ml into 25 ml  volumetric flasks  to  
acquire  12 µg/ ml  solution  made  up  with  Simulated Gastric Fluid (without 
Enzyme).  
 
7.1.6. Determination of drug-polymer compatibility (Patil S.V., et al., 2009) 
Drug polymers studies holds great importance in designing a formulation. In 
drug formulation it is essential to evaluate the possible interactions between the active 
principle and the polymers, as the choice of the polymers should be performed in 
relation to the drug delivery, to their compatibility with the same drug and to the 
stability of the final product. The  proper  design  and  formulation  of  a  dosage  form  
requires  consideration  of  the physical, chemical and biological characteristics of all 
drug substances and excipients to be used in the fabricating the product. Each polymer 
used in the formulations was blended with the drug levels that are realistic with respect 
to the final dosage form. 
A] Fourier transforms infra-red (FTIR) spectroscopy   (Patil S.V., et al., 2009; IP, 
2007; http://en.wikipedia.org/wiki/Fourier_transform_infrared_spectroscopy) 
FTIR study was carried out to check compatibility of drug with polymers. 
Infrared spectrum  of  Celecoxib  was  determined  on  Fourier  transform  Infrared  
Spectrophotometer using KBr dispersion method. The base line correction was done 
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using dried potassium bromide. Then the spectrum of dried mixture of drug and 
potassium bromide was run followed by drug with various polymers by using FTIR 
spectrophotometer. The absorption maximums in spectrum obtained with the substance 
being examined correspond in position and relative intensity to those in the reference 
spectrum. 
 
 
 
 
Figure 7.1 Compatibility studies 
 
B] Differential Scanning Calorimetry (DSC) (Patil S.V., et al., 2009; Aulton  M. E., 
2002; http://en.wikipedia.org/wiki/Differential_scanning_calorimetry) 
Any possible drug polymer interaction can be studied by thermal analysis. The 
DSC study was performed on pure drug Celecoxib, Celecoxib with HPMC K15M, 
Celecoxib with Ethyl cellulose and Celecoxib with HPMC K15M and Ethyl cellulose. 
The mixture of drug with polymers to maximize the like hood of obscuring an 
interaction. Mixture should be examined under Nitrogen to eliminate oxidative and 
pyrolytic effect at a standard heating rate (10°C/minute) on DSC. Over a temperature 
range, which will encompass any thermal changes due to the mixture of drug with 
 Non-effervescent floating microparticulates of Celecoxib Experimental Work 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 75 
polymers. Thermo grams of pure drug are used as a reference.      
Appearance or disappearance of one or more peaks in thermo grams of drug with 
polymer are considered as an indication of interaction. 2 mg of sample were heated in a 
hermetically sealed aluminum pans in the temperature range of 50 to 250 ºC at heating 
rate of 10 ºC / min under nitrogen flow of 30 ml / min. 
 
7.2 PREPARATION OF NON-EFFERVESCENT FLOATING 
MICROPARTICULATES: (Satish Singh., et al., 2012) 
The non-effervescent floating microparticulates were prepared by solvent diffusion 
and evaporation method, by using a drug and polymers in different concentrations. The 
formulations were designated as F1, F2, F3, F4, F5, F6, F7, F8 and F9 respectively. 
Table7.2: The compositions of formulations 
Ingredients 
(gm) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Celecoxib 1 1 1 1 1 1 1 1 1 
HPMC K15M 0.25 - 0.5 0.5 - 1 1 0.5 0.75 
Ethyl cellulose 0.25 0.5 - 0.5 1 - 0.5 1 0.75 
 
Solvent diffusion and evaporation method: 
Microparticulates were prepared by using the technique in which polymers 
(HPMC K15M and Ethyl Cellulose) were dissolved in 15ml equimolar mixture of 
dimethyl formamide and dichloromethane and stirred for 5 minutes using magnetic stirrer 
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at 100 rpm. Drug was added into the polymer solution with continuous stirring for 5 
minutes at 100 rpm. This solution was slowly poured into 100 ml light liquid paraffin 
containing 2.0% w/w Tween-80 and stirred using mechanical stirrer for 8 hours at 750 
rpm. Finally developed microparticulates were filtered and washed with petroleum ether 
and dried at room temperature for 4-6 hours. 
 
7.3 EVALUATION OF NON-EFFERVESCENT FLOATING 
MICROPARTICULATES:  
 
A] Appearance: 
The microparticulates were visually observed for physical appearance. 
 
B] Percentage Yield: (Venkatesan P et al., 2011; Bindhu Madhavi., et al., 2011 ) 
The percentage yield was calculated from the ratio of filtered and dried 
microparticulates amount of each formulation to total solid material (non-volatile) content 
in the dispersed phase. The percentage yield of the prepared microparticulates was 
calculated by using the following formula. 
 
 Weight of Microparticulates  
Percentage Yield = -------------------------------------------------------- x 100 
 (Weight of Drug + Polymer taken) 
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Micromeritic Properties: 
C] Bulk Density: (USP, 2012) 
Accurately weighed quantity of floating microparticulates from each formula was 
lightly shaken to break any agglomerates formed and it was introduced in to a 10 ml 
measuring cylinder. The volume occupied was measured which gave bulk volume. The 
bulk density of floating microparticulates was determined using the following formula. 
Bulk density (g/mL) = Weight of microparticulates taken / Bulk volume 
 
D] Tapped Density: Yasunori et al (2003) 
 Accurately weighed quantity of floating microparticulates was transferred into a 10 
ml measuring cylinder. After observing the initial volume of floating microsphere, carry 
out 500 taps from 3mm of height. Change in volume was noted and the tapped density was 
calculated according to the formula. 
Tapped density = Weight of microparticulates taken / Tapped volume 
 
E] Carr’s Compressibility Index: (USP, 2012) 
It is a simple index that can be determined on small quantities of powder. In 
theory, the less compressible a material the more flowable it is. The compressibility 
indices of the powder blends was determined using following formula, 
 Tapped Density - Bulk density  
Carr’s Compressibility Index = ----------------------------------------------- x 100 
 Tapped Density 
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F] Hausner’s Ratio: (USP, 2012) 
 Hausner’s ratio is the ratio between tapped density and bulk density. Hausner’s 
ratio less than 1.25 indicates good flow properties while Hausner’s ratio greater than 1.25 
shows poor flow of granules. 
Hausner’s Ratio = Tapped Density / Bulk Density 
 
G] Angle of Repose: (USP, 2012) 
 The dried microparticulates were allowed to fall freely through a funnel fixed at 
height of 3 cm on a horizontal surface and the angle of repose (θ) was measured. 
θ = tan-1(h/r) 
Where h is the height of the heap, r is the radius. 
 
Table 7.3 Relationship between Flow property, Angle of Repose, Carr’s Index and 
Hausner’s Ratio 
Flow Property 
Angle of Repose 
(°C) 
Carr’s 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
Excellent 25–30 10 1.00–1.11 
Good 31–35 11–15 1.12–1.18 
Fair—aid not needed 36–40 16–20 1.19–1.25 
Passable—may hang up 41–45 21–25 1.26–1.34 
Poor—must agitate, vibrate 46–55 26–31 1.35–1.45 
Very poor 56–65 32–37 1.46–1.59 
Very, very poor >66 >38 >1.60 
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H] Particle size distribution: (Sathish Singh, et al., 2012) 
 Particle size distribution of microparticulates was determined by Malvern Particle 
size analyzer (Master Seizer 2000) by solvent dispersion method. Approximately 1 g of 
microparticulates was used for determination of microparticulates.  
 
I] Scanning electron microscopy (SEM) (USP, 2012) 
The surface morphology (roundness, smoothness and formation of aggregate and 
the size of microparticulates formulation were studied by Scanning electron microscopy. 
The solid sample of microparticulates were dispersed in water for SEM analysis was 
coated with a thin layer of platinum or gold using the PVD process at a 30MA current 
from the distance of 50nm. Photographs were taken within the range of 50-500 
magnification. 
 
J] Loss on Drying: (Sathish Singh, et al., 2012) 
Loss on drying is the loss of weight expressed as percentage w/w resulting from 
water and volatile matter of any kind that can be driven off under specified condition. 
The accurately weighed  0.5 gm  of  microparticulates  was  transferred  instoppered-
glass  shallow  weighing  bottle  and accurately weighed the bottle. The bottle was 
transferred in oven and microparticulates were dried at 105°C for 3 hours. The bottle 
was removed from oven and reweighed; loss on drying was calculated by following 
equation.  
 
    [Initial Weight taken - Final Weight after drying] 
Loss on Drying = ------------------------------------------------------------------- x 100 
   Initial Weight taken 
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7.3.1 Buoyancy Test: (Sathish Singh, et al., 2012) 
Weighed amount of microparticulates were sprinkled over the surface of 900 ml 
stimulated gastric fluid USP dissolution apparatus (Type II). The medium was agitated 
with a paddle rotating at 50 rpm for 12 hours. The floating and the settled portions of 
microparticulates were recovered separately. The microparticulates were dried and 
weighed. Buoyancy percentage was calculated as the ratio of the mass of the 
microparticulates that remained floating and the total mass of the microparticulates. 
 
    Weight of the floating microparticulates x 100 
% Buoyancy = -----------------------------------------------------------------------------------------  
(Weight of the floating microparticulates + settled microparticulates) 
 
 
 
Figure 7.2 Top view showing floating microparticulates in Buoyancy test  
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Figure 7.3 Bottom view showing settled microparticulates in Buoyancy test  
 
Figure 7.4 Floating and settled microparticulates in Buoyancy test  
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Table 7.4 Parameters for Buoyancy Test 
S. No. Parameter Specification 
1 Apparatus USP type II apparatus (Paddle type) 
2 Temperature 37 + 0.5° C 
3 Initial volume 900ml 
4 Speed 50 rpm 
5 Drawn volume 10 ml 
6 Running time 12 hours in Simulated gastric fluid 
7 Medium replacement at every 1 hour interval 
 
 
7.3.2 Entrapment Efficiency: (Sathish Singh, et al., 2012) 
 Crushed microparticulates (equivalent to 100 mg of active substance) 
were dissolved in methanol to dissolved the drug completely and transferred slowly into 
900 ml in SGF media (without enzyme) and stirred for 20 minutes. The solution was then 
filtered and 10 ml of the solution was made upto 100ml with SGF media (without 
enzyme). The samples were analyzed at λ max 249 nm against SGF as a blank using UV 
visible spectrophotometer. 
 
7.3.3 In-vitro Drug release studies: (Sathish Singh, et al., 2012) 
 Dissolution test was performed by using USP tablet dissolution apparatus 
Type I (Veego scientific VDA-8DR). The dissolution medium used was 900 ml of SGF 
without enzyme. The weighed quantity of microparticulates equivalent to 100 mg of 
active substance filled into capsule cell and kept into dissolution medium which was set 
at 37 ± 0.5 °C and stirred at 50 rpm. To keep the microparticulates in dissolution medium 
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baskets of 100 meshes were used instead of paddles. 10 ml samples were withdrawn at 
predetermined time intervals of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours and same 
volume of medium was replaced. The withdrawn sample were diluted to 100 ml with 
SGF without enzyme and analyzed in UV visible spectrophotometer at λ max 249 nm. 
Table 7.5 Parameters for in-vitro drug release 
S. No. Parameter Specification 
1 Apparatus USP type I apparatus (Basket type) 
2 Temperature 37 + 0.5° C 
3 Initial volume 900ml 
4 Speed 50 rpm 
5 Drawn volume 10 ml 
6 Running time 12 hours in SGF without enzyme 
7 Medium replacement at every 1 hour interval 
 
7.3.4 Kinetics of in-vitro drug release: (Amitava G.,et.al., 2009: Harris M.S.,et 
al.,2006)        
To study the release kinetics of in-vitro drug release, data was applied to kinetic 
models such as Zero order, First order, Higuchi and Korsmeyer- Peppas. 
 Zero order model:  
Qt = Q0 + K0 t 
Qt is the amount of drug dissolved in time t  
Q0 is the initial amount of drug in the solution (most times, Q0 = 0)  
K0 is the zero order release constant expressed in units of 
concentration/time. 
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 First order model:  
log C = log C0 - Kt / 2.303 
C0 is the initial concentration of drug 
t is the time 
K is first order rate constant expressed in units of time
-1
 
 
 Higuchi model: 
f t = Q = KH x t
0.5 
KH is the Higuchi dissolution constant 
Q is the amount of drug released in time t 
 
 Korsmeyer-peppas model: 
Mt / M0 = K t
n  
Mt / M0 is a fraction of drug released at time t  
k is the release rate constant  
n is the release exponent 
 
Table 7.6 Diffusion exponent and solute release mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
< 0.5 Quasi-Fickian diffusion 
0.5 Fickian diffusion 
0.5 < n < 1.0 Anomalous (non-Fickian) diffusion 
1.0 Case-II transport 
> 1.0 Super case-II transport 
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The value of n give an indication of the release mechanism; when n=1, the release rate is 
independent of time (Zero order) (Case II transport), n=0.5 for fickian diffusion and when 
0.5<n>1.0, diffusion and non fickian transport are implicated. Lastly, when n>1.0 super 
case II transport is apparent. The interpretation release profile of all formulation data was 
based on the value of the resulting regression coefficient. 
 
7.3.5 Ex-vivo permeation studies: (Sathish Singh, et al., 2012) 
 Goat stomach of scarified goat collected from slaughter house. Stomach 
was cleaned with simple saline. The non effervescent floating microparticulates 
equivalent to 100 mg of active substance was placed in the cylindrical cup which was 
connected to shaft and membrane tied with the end of cylindrical cup. The cup of tied 
membrane was immersed in USP dissolution jar containing 900 ml SGF at 37 ± 2ºC and 
stirred at 100 rpm. 10 ml samples were withdrawn at predetermined time intervals of 1, 2, 
3, 4, 5, 6, 7, 8, 9, 10, 11 and 12 hours and same volume of medium was replaced with 
fresh medium. The withdrawn sample were diluted to 100 ml with SGF without enzyme 
and analyzed in UV visible spectrophotometer at λ max 249 nm. 
Table 7.7 Parameters for ex-vivo Permeation studies 
S. No. Parameter Specification 
1 Apparatus USP dissolution apparatus 
2 Temperature 37 + 2° C 
3 Initial volume 900ml 
4 Speed 100 rpm 
5 Drawn volume 10 ml 
6 Running time 12 hours in SGF 
7 Medium replacement at every 1 hour interval 
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Figure 7.5 Ex-vivo permeation study using goat stomach membrane  
 
7.4 Stability Studies: (Sathish Singh, et al., 2012) 
The purpose of stability testing was to obtain a stable product which assures its 
safety. Floating microparticulates (equivalent to 100 mg of active substance) was filled 
into capsule shell. Floating microparticulates were tested for three months stability 
studies at room temperature. In-vitro drug released and buoyancy parameters were 
analyzed at the time interval of one month.  
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8. RESULTS AND DISCUSSION 
 
PREFORMULATION STUDIES 
8.1. Identification of drug 
A] By FTIR spectroscopy 
The FTIR spectrum of Celecoxib was shown in Figure 8.1 and the interpretations of 
FTIR frequencies were represented in Table 8.1 
 
Figure 8.1: FTIR spectrum of Celecoxib 
Table 8.1 Characteristic frequencies in FTIR spectrum of Celecoxib 
Wave No. (cm
-1
) Observed Wave No’s Inference 
780 – 820 cm–1 794.99 Aromatic CH stretching 
1150 - 1350 cm
–1
 
1135.00, 1163.28, 1229.95, 
1277.21, 1348.10  
S=O stretching (Sulfonamide 
group) 
1550 - 1600 cm
–1
 1562.82 H stretching 
3200 - 3500 cm
–1
 3233.92, 3341.05 NH2 stretching 
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Interpretation of FTIR Spectrum 
Major functional groups like NH2 stretching, H stretching, Aromatic CH stretching, and 
S=O stretching (Sulfonamide group) were present in Celecoxib showed characteristic 
peaks in FTIR spectrum. The major peaks were identical to functional group of 
Celecoxib. Hence, the sample was confirmed as Celecoxib. 
 
B] By Melting point: 
Melting point values of Celecoxib drug was found to be in range of 160°C to 164°C, 
which was represented in Table 8.2. The observed melting point for Celecoxib was 
161.67 ± 0.58 °C, which meets the specification limit. 
Table 8.2 Melting point of Celecoxib 
S.No. Melting Point Average 
Standard 
Deviation 
Range* 
1 162°C 
161.67 0.58 161.67 ± 0.58 °C 2 162°C 
3 161°C 
*Range is expressed as Mean ± S.D., n = 3. 
 
  
 Non-effervescent floating microparticulates of Celecoxib Results and Discussion 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 90 
8.2. Physicochemical parameters 
A] Organoleptic properties 
Table 8.3 Organoleptic properties of Celecoxib 
 Properties  Specification Observation 
Color White or almost white color White color 
Nature Amorphous or crystalline powder Amorphous powder 
Odour NA Odourless 
 
B] Solubility study 
 Solubility of Celecoxib in different solvents was represented in Table 8.4. 
Table 8.4 Solubility profile of Celecoxib 
S. 
No. 
Solvent 
Parts of solvent required 
per part of solute 
Inference 
1 Water 10,000 Practically Insoluble 
2 Methanol 10 Freely Soluble 
3 Ethanol (95%) 20 Soluble 
4 0.1N Hydrochloric Acid 10,000 Practically Insoluble 
5 O.1N Sodium Hydroxide 7 Freely Soluble 
6 Dimethyl formamide 7 Freely Soluble 
 
From the above data the solubility of Celecoxib was confirmed in various polar and 
non polar solvents. 
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C] Loss on drying: 
The percentage loss on drying of microparticulates after 3 hours was represented in Table 
8.5. 
Table 8.5  Loss on drying for Celecoxib 
S.No. 
Percentage 
LOD 
Average 
Standard 
Deviation 
Range* 
1 0.4044 
0.436 % 0.028 0.436 ± 0.028 % 2 0.4563 
3 0.4481 
*Range is expressed as Mean ± S.D., n = 3 
 
8.3. Determination of λ max 
Determination of λ max for Celecoxib in 0.2N Sodium Hydroxide: 
The absorption maximum for Celecoxib in 0.2N S o diu m  H y dr ox i d e was 
found to be 252 nm and absorption maximum was represented in Figure 8.2. 
 
Figure 8.2 λ max observed for Celecoxib in 0.2N Sodium Hydroxide 
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Determination of λ max for Celecoxib in SGF (without enzyme): 
The absorption maximum for Celecoxib in Simulated gastric fluid (without 
enzyme) was found to be 249 nm and   absorption maximum was represented in 
Figure 8.3. 
 
Figure 8.3 λ max observed for Celecoxib in SGF (without enzyme) 
 
8.4 Development of standard curve of Celecoxib: 
Development of standard curve of Celecoxib in 0.2 N Sodium Hydroxide 
Absorbance obtained for various concentrations of Celecoxib in 0.2N 
S od iu m H yd r ox i d e  were represented in Table.8.6.and Figure 8.4. The graph of 
absorbance Vs concentration for Celecoxib was found to be linear in the concentration 
range of 4 to 20 μg/ml. The calibration curve parameters were represented in Table: 
8.7 and the drug obey Beer- Lambert’s law. 
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Table: 8.6 Data of concentration Vs absorbance for Celecoxib in 0.2N Sodium 
hydroxide 
S.No Concentration (mcg/ml) Absorbance at 252nm 
1 4 0.145 
2 8 0.301 
3 12 0.453 
4 16 0.594 
5 20 0.740 
 
 
Figure 8.4  Standard graph of Celecoxib in 0.2N Sodium hydroxide 
Table 8.7 Data for calibration curve Parameters of Celecoxib in 0.2N Sodium hydroxide 
S. No   Parameters  Values 
1 Correlation coefficient (r) 0.99989 
2 Slope (m) 0.03714 
3 Intercept (c) 0.00081 
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Development of standard curve of Celecoxib in SGF (without enzyme): 
Absorbance obtained for various concentrations of Celecoxib in SGF (without 
enzyme) were represented in Table.8.8.and Figure 8.5. The graph of absorbance Vs 
concentration for Celecoxib was found to be linear in the concentration range of 4 to 
20 μg/ml. The calibration curve parameters were represented in Table: 8.9 and the 
drug obey Beer- Lambert’s law. 
 
Table 8.8 Data of concentration Vs absorbance for Celecoxib in SGF (without enzyme) 
S.No Concentration (mcg/ml) Absorbance at 249nm 
1 4 0.127 
2 8 0.236 
3 12 0.353 
4 16 0.475 
5 20 0.604 
 
 
Figure 8.5 Standard graph of Celecoxib in SGF (without enzyme) 
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Table 8.9 Data for calibration curve Parameters of Celecoxib in SGF (without enzyme) 
S. No   Parameters  Values 
1 Correlation coefficient (r) 0.99971 
2 Slope (m) 0.029864 
3 Intercept (c) 0.00052 
 
 
8.5 Determination of percentage purity of drug: 
Percentage purity of Celecoxib in 0.2N Sodium hydroxide:  
The percentage purity of Celecoxib was calculated by using calibration graph method and 
represented in Table 8.10 
Table 8.10 Percentage purity of Celecoxib in 0.2N Sodium hydroxide 
S.No. Percentage Purity (% w/w) Average (% w/w) 
1 99.90 % 
100.28 % 2 100.80 % 
3 100.17 % 
 
The reported percentage purity of Celecoxib in 0.2N Sodium hydroxide was 100.28%, 
which is within the USP specification range of 98.0% to 102.0% 
 
Percentage purity of Celecoxib in SGF (without enzyme):  
The percentage purity of Celecoxib was calculated by using calibration graph method and 
represented in Table 8.11 
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Table 8.11 Percentage purity of Celecoxib in SGF (without enzyme) 
S.No. 
Percentage Purity       
(% w/w) 
Average              
(% w/w) 
1 100.03 
99.75 % 2 99.47 
3 99.75 
 
The reported percentage purity of Celecoxib in SGF (without enzyme) was 99.75%, 
which is within the USP specification range of 98.0% to 102.0% 
 
8.6 Determination of drug-polymer compatibility: 
A] By FTIR spectroscopy: 
The FTIR spectrums of Celecoxib with polymers (HPMC K15M and Ethyl 
cellulose) used in formulation were showed in Figures 8.6 to 8.9, and their interpretations 
were represented in Table 8.12. 
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Figure 8.6 FTIR spectrum of Celecoxib 
 
 
Figure 8.7 FTIR spectrum of Celecoxib with HPMC K15M 
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Figure 8.8 FTIR spectrum of Celecoxib with Ethyl cellulose 
 
 
Figure 8.9 FTIR spectrum of Celecoxib with HPMC K15M and Ethyl cellulose 
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Table 8.12 Interpretation of FTIR Spectrum 
Specification 
Celecoxib 
drug 
Celecoxib 
with 
HPMC 
K15M 
Celecoxib 
with 
Ethyl 
Cellulose 
Celecoxib 
with 
HPMC 
K15M 
and Ethyl 
Cellulose 
Inference 
Wave No. (cm
-1
) 
780 – 820 cm–1 794.99 794.73 794.45 793.47 
Aromatic CH 
stretching 
1150-1350 cm
–1
 
1135.00, 
1163.28, 
1229.95, 
1277.21, 
1348.10 
1135.05, 
1163.67, 
1229.73, 
1276.98, 
1347.85 
1135.07, 
1163.70, 
1229.32, 
1277.41, 
1348.30 
1135.72, 
1163.64, 
1228.30, 
1276.85, 
1348.50 
S=O stretching 
(Sulfonamide 
group) 
1550-1600 cm
–1
 1562.82 1562.43 1561.74 1561.95 H stretching 
3200-3500 cm
–1
 
3233.92, 
3341.05 
3235.24, 
3342.05 
3235.20, 
3342.05 
3236.56, 
3343.40 
NH2 stretching 
 
The major peaks observed in drug spectrum corresponds with peaks observed in drug 
with polymer spectrum. From the FTIR spectrums compared; it could indicate that there 
was no incompatibility between drug and polymer. 
 
B] By DSC thermal analysis: 
The DSC thermograms of Celecoxib with polymers (HPMC K15M and Ethyl 
cellulose) used in formulations were represented in Figures 8.10 to 8.13, and their 
comparison were represented in Table 8.13. 
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Figure 8.10 DSC thermogram of Celecoxib 
 
 
Figure 8.11 DSC thermogram of Celecoxib with HPMC K15M 
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Figure 8.12 DSC thermogram of Celecoxib with Ethyl cellulose 
 
 
Figure 8.13 DSC thermogram of Celecoxib with HPMC K15M and Ethyl cellulose 
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Table 8.13: Comparison of DSC thermograms 
DSC Thermogram 
Onset Temperature 
(°C) 
Peak Temperature 
(°C) 
Celecoxib 162.10 ° C 164.05° C 
Celecoxib with HPMC K15M 161.30° C 163.43° C 
Celecoxib with Ethyl Cellulose 161.30° C 163.43° C 
Celecoxib with HPMC K15M and Ethyl 
Cellulose 
161.30° C 163.43° C 
 
The drug and polymer interaction was studied by using DSC. Celecoxib exhibits a 
sharp endothermic peak which is corresponding with its melting point. The endothermic 
peak temperature of Celecoxib corresponds with the endothermic peak temperature of 
drug with polymer. No interaction was found between drug and polymers.  
 
8.7 PREPARATION OF NON-EFFERVESCENT FLOATING 
MICROPARTICULATES: 
 Nine different formulations of non-effervescent floating microparticulates were 
prepared by solvent diffusion and evaporation method, by using a drug and with polymers 
in different concentrations. Polymers HPMC K15M and Ethyl cellulose were used in 
formulations. The formulations were designated as F1, F2, F3, F4, F5, F6, F7, F8 and F9 
respectively. All the formulated microparticulates were taken for further evaluation. 
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8.8 EVALUATION OF NON-EFFERVESCENT FLOATING 
MICROPARTICULATES 
A] Appearance: 
The prepared microparticulates were visually observed, and found to be white crystalline 
mass. 
 
B] Percentage Yield: 
The percentage yield of microparticulates were in the range of 69.05 % to 83.82 %. 
Maximum yield was obtained in Formulation F5 (83.82 %), followed by F8 (82.53 %), F3 
(79.77 %), F4 (79.38 %) and F9 (79.06 %). The percentage yield of the prepared 
microparticulates was represented in Table 8.14 and Figure 8.14. 
Table 8.14 Percentage yield of microparticulates 
Formulation 
No. 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Percentage 
Yield  
(% w/w) 
77.15 69.05 79.77 79.38 83.82 76.73 70.98 82.53 79.06 
 
 Non-effervescent floating microparticulates of Celecoxib Results and Discussion 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 104 
 
Figure 8.14 Percentage yield of microparticulates 
 
8.8.1 MICROMERITIC PROPERTIES: 
Bulk density, Tapped Density, Carr’s Index, Hausner’s ratio and Angle of repose: 
The observed bulk density was in the range of 0.686 to 0.822 g/mL, Tapped 
density was in the range of 0.735 to 0.892 g/mL, Carr’s index was in the range of 6.53 to 
7.91 %, Hausner’s ration was in the range of 1.07 to 1.09, and angle of repose was in the 
range of 21.18 to 24.09 °C. From the above data, it is found that all the formulations were 
having excellent flow properties. Bulk density, Tapped density, Carr’s compressibility 
index, Hausner’s ratio and Angle of repose of non effervescent floating microparticulates 
were represented in Table 8.15 and Figure 8.15 to 8.18.  
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Table 8.15 Micromeritic properties of microparticulates 
Formulation 
No. 
Bulk Density 
(g/mL)* 
Tapped 
Density 
(g/mL)* 
Carr's 
Compressibility 
Index (%) 
Hausner’s 
Ratio 
Angle of 
Repose (°C)* 
F1 
0.822 ± 
0.022 
0.892 ± 
0.026 
7.91 1.09 24.09 ± 0.34 
F2 
0.803 ± 
0.012 
0.868 ± 
0.016 
7.51 1.08 23.99 ± 0.88 
F3 
0.799 ± 
0.010 
0.866 ± 
0.011 
7.69 1.08 22.86 ± 0.91 
F4 
0.787 ± 
0.012 
0.851 ± 
0.016 
7.51 1.08 22.55 ± 0.90 
F5 
0.686 ± 
0.007 
0.735 ± 
0.008 
6.53 1.07 22.39 ± 0.90 
F6 
0.742 ± 
0.059 
0.800 ± 
0.068 
7.17 1.08 21.18 ± 0.67 
F7 
0.711 ± 
0.038 
0.763 ± 
0.044 
6.69 1.07 21.33 ± 0.41 
F8 
0.782 ± 
0.021 
0.844 ± 
0.026 
7.33 1.08 22.77 ± 0.56 
F9 
0.817 ± 
0.018 
0.885 ± 
0.020 
7.69 1.08 21.80 ± 0.39 
 
* The values were expressed as Mean ± S.D., n = 3. 
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Figure 8.15 Bulk density and Tapped Density of microparticulates 
 
 
Figure 8.16 Carr’s Compressibility Index of microparticulates 
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Figure 8.17 Hausner’s Ratio of microparticulates 
 
 
Figure 8.18 Angle of Repose of microparticulates 
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8.8.2 Particle size distribution: 
Particle size distribution of microparticulates was determined using Malvern 
Particle size analyzer (Master Seizer 2000) by solvent dispersion method. The observed 
particle size of non effervescent floating microparticulates of formulation F5 was found to 
be 146.01 µm. The results obtained were represented in Table 8.16 and Figure 8.19. 
Table 8.16 Particle size distribution of microparticulates 
Formulation No. Particle Size (µm) 
F5 146.01 µm 
 
 
Figure 8.19 Particle size distribution of microparticulates 
 Non-effervescent floating microparticulates of Celecoxib Results and Discussion 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 109 
  
8.8.3 Scanning Electron Microscopy (SEM) 
Surface morphology and shape characteristics of microparticulates for 
formulation F5 was evaluated by means of scanning electron microscopy. The SEM 
photographs of the microspheres revealed that the microparticulates were spherical with 
rough, hollow surface and slightly aggregated. The SEM photographs were provided in 
Figure 8.20. 
 
Figure 8.20 Scanning Electron Microscopy of microparticulates 
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8.8.4 Loss on Drying: 
 Loss on drying of microparticulates was determined at 105°C for 3 hours. The 
loss on drying of all the formulated microparticulates were not more than 1 % w/w. From 
the results obtained in Loss on drying reveals that the microparticulates were dried 
efficiently at room temperature during formulation. The obtained results were represented 
in Table 8.17 and Figure 8.21. 
Table 8.17 Loss on drying of microparticulates 
Formulation 
No. 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Loss on 
Drying* 
(% w/w) 
0.878 
± 
0.003 
% 
0.912 
± 
0.009 
% 
0.879 
± 
0.002 
% 
0.859 
± 
0.003 
% 
0.874 
± 
0.001 
% 
0.880 
± 
0.001 
% 
0.923 
± 
0.001 
% 
0.841 
± 
0.002 
% 
0.850 
± 
0.004 
% 
* The values were expressed as Mean ± S.D., n = 3. 
 
Figure 8.21 Loss on drying of microparticulates 
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8.8.5 Buoyancy Test and Entrapment efficiency: 
 The buoyancy percentage of non effervescent floating microparticulates was 
found to be in the range of 56.30 to 62.56 % Formulation F5 shows higher buoyancy 
percentage of 62.56%. The entrapment efficiency of non effervescent floating 
microparticulates was found to be in the range of 68.92 to 88.12 % Formulation F5 shows 
higher entrapment efficiency of 88.12%. The buoyancy percentage and entrapment 
efficiency of microparticulates were increased in formulations containing higher ratio of 
ethyl cellulose. The Buoyancy test and Entrapment efficiency of microparticulates were 
represented in Table 8.18 and Figure 8.22. 
 
Table 8.18 Buoyancy test and Entrapment efficiency of microparticulates 
Formulation No. Buoyancy Test* (%) 
Entrapment 
Efficiency* (%) 
F1 57.87 ± 1.85 70.10 ± 1.52 
F2 59.10 ± 1.37 80.96 ± 1.65 
F3 60.31 ± 0.85 68.92 ± 2.30 
F4 56.30 ± 1.69 74.80 ± 1.06 
F5 62.56 ± 1.43 88.12 ± 1.84 
F6 58.50 ± 1.23 69.68 ± 0.92 
F7 56.81 ± 3.16 71.27 ± 1.63 
F8 57.64 ± 0.77 77.51 ± 1.18 
F9 56.73 ± 1.35 76.05 ± 0.74 
 
* The values were expressed as Mean ± S.D., n = 3. 
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Figure 8.22 Buoyancy test and Entrapment efficiency of microparticulates 
 
8.8.6 In-vitro Drug release studies: 
 The percentage drug release of non effervescent floating microparticulates were in 
the range of 64.23 to 83.52 %. Highest percentage drug release was found in F5 
(83.52%), followed by F2 (76.09%), F8 (74.28%) and F9 (73.17%). From the results, it is 
evident that the formulations with increased ratio of ethyl cellulose shows increased 
percentage drug release. 
The results of in-vitro drug release studies were represented in Table 8.19, and the 
respective plot for in-vitro drug release of Formulations F1 to F9 were represented in 
Figure 8.23 to 8.31. Graphical representation of in-vitro drug release studies were 
represented in Figure 8.32.  
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Table 8.19 In-vitro drug released profile of microparticulates for formulations F1 to F9 
Time in 
Hours 
Formulations * 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Hour 11.49 14.01 10.39 12.70 16.72 12.00 12.20 13.91 14.11 
2 Hours 18.23 19.53 17.52 18.93 21.44 15.71 18.12 19.33 19.43 
3 Hours 26.76 30.88 25.06 27.67 30.38 23.45 27.57 31.99 32.29 
4 Hours 33.09 37.61 31.49 34.20 42.13 31.08 33.19 38.62 40.83 
5 Hours 43.44 47.26 41.23 45.25 52.08 42.74 42.74 50.07 51.48 
6 Hours 47.36 54.69 46.45 49.47 57.60 46.45 49.27 57.00 55.09 
7 Hours 51.78 58.81 50.27 53.79 63.83 50.47 52.68 60.32 58.21 
8 Hours 54.99 65.44 52.38 57.40 71.87 54.69 57.00 66.24 63.53 
9 Hours 58.01 68.65 54.79 59.91 75.48 58.71 59.41 68.45 65.64 
10 Hours 61.92 70.96 60.01 63.33 77.69 60.11 62.83 70.46 67.85 
11 Hours 63.83 74.18 61.82 66.64 80.41 62.43 65.64 73.07 70.76 
12 Hours 65.74 76.09 64.23 69.96 83.52 65.54 68.45 74.28 73.17 
 
* The values were expressed as Mean ± S.D., n = 3.  
  
 Non-effervescent floating microparticulates of Celecoxib Results and Discussion 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 114 
 
Figure 8.23 Plot of in-vitro drug released for Formulation F1 
 
Figure 8.24 Plot of in-vitro drug released for Formulation F2 
 
Figure 8.25 Plot of in-vitro drug released for Formulation F3 
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Figure 8.26 Plot of in-vitro drug released for Formulation F4 
 
Figure 8.27 Plot of in-vitro drug released for Formulation F5 
 
Figure 8.28 Plot of in-vitro drug released for Formulation F6 
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Figure 8.29 Plot of in-vitro drug released for Formulation F7 
 
Figure 8.30 Plot of in-vitro drug released for Formulation F8 
 
Figure 8.31 Plot of in-vitro drug released for Formulation F9  
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Figure 8.32 Plot of comprehensive in-vitro drug released profile of microparticulates for formulations F1 to F9
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8.8.7 Kinetics of in-vitro drug release: 
The kinetics of in-vitro drug release studies were determined by applying the drug 
release data to various kinetic models such as zero order, first order, Higuchi and 
Korsmeyer - Peppas. From the data and graphical representations, The interpretation 
release profile of Celecoxib non effervescent floating microparticulates were based on the 
regression coefficient values. Formulation F5 showed best fit model as first order 
kinetics. The results obtained were represented in Table 8.20 and the plot for kinetics of 
in-vitro drug released were represented in Figures 8.33 to 8.41. 
Table 8.20 Kinetics of in-vitro drug release of microparticulates 
Formulation 
No. 
Zero 
Order 
First 
Order 
Higuchi  Peppas  
Best Fit 
Model 
R
2
 R
2
 R
2
 R
2
 n 
F1 0.9326 0.9917 0.9894 0.9949 0.6403 Peppas 
F2 0.9428 0.9975 0.9859 0.9928 0.6569 First Order 
F3 0.9372 0.9909 0.9881 0.9955 0.6519 Peppas 
F4 0.9346 0.9939 0.9887 0.9938 0.6348 First Order 
F5 0.9473 0.9969 0.9838 0.9897 0.6519 First Order 
F6 0.9423 0.9921 0.9833 0.9876 0.6557 First Order 
F7 0.9375 0.9936 0.9877 0.9933 0.6428 First Order 
F8 0.9263 0.9934 0.9862 0.9896 0.6531 First Order 
F9 0.9126 0.9905 0.9895 0.9889 0.6306 First Order 
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Figure 8.33 Best fit model (Peppas) for Formulation F1 
 
Figure 8.34 Best fit model (First order) for Formulation F2 
 
Figure 8.35 Best fit model (Peppas) for Formulation F3 
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Figure 8.36 Best fit model (First order) for Formulation F4 
 
Figure 8.37 Best fit model (First order) for Formulation F5 
 
Figure 8.38 Best fit model (First order) for Formulation F6 
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Figure 8.39 Best fit model (First order) for Formulation F7 
 
Figure 8.40 Best fit model (First order) for Formulation F8 
 
Figure 8.41 Best fit model (First order) for Formulation F9 
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8.8.8 Ex-vivo Permeation Studies: 
 The ex-vivo permeation study was performed using membrane obtained from goat 
stomach. The best formulation was selected based on the in-vitro drug release, Buoyancy 
percentage and entrapment efficiency.  Formulation F5 results showed higher results of 
in-vitro drug release, Buoyancy percentage and entrapment efficiency, when compared 
with other formulations, so F5 was selected as best formulation. 
The kinetics of ex-vivo permeation study was represented in Table 8.22 and the 
plot for kinetics of ex-vivo permeation study was represented in Figure 8.43. 
Table 8.21 Ex-vivo Permeation Studies for formulation F5 
Time 
(in Hours) 
Ex-vivo Permeation Studies* (F5) 
(% Drug Released) 
1 Hour 5.72 ± 1.67 
2 Hours 10.60 ± 0.75 
3 Hours 15.39 ± 1.23 
4 Hours 20.97 ± 0.85 
5 Hours 25.75 ± 1.10 
6 Hours 30.84 ± 0.54 
7 Hours 36.42 ± 0.28 
8 Hours 41.10 ± 1.06 
9 Hours 44.99 ± 1.02 
10 Hours 51.66 ± 1.02 
11 Hours 56.45 ± 0.67 
12 Hours 62.02 ± 1.34 
 * The values were expressed as Mean ± S.D., n = 3. 
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The percentage drug released at ex-vivo permeation study for formulation F5 at 12 
hours was found to be 62.02 %.  The percentage drug released at ex-vivo permeation 
study (62.02 %) was found lesser than the percentage drug released at in-vitro drug 
release study (83.52 %) for formulation F5. The results of ex-vivo permeation studies was 
represented in Table 8.21, and the plot for ex-vivo permeation studies were shown in 
Figure 8.42. 
The kinetics of ex-vivo permeation study was determined by applying the drug 
released data to various kinetic models such as zero order, first order, Higuchi and 
Korsmeyer - Peppas. The best fit model for kinetics of ex-vivo permeation study was 
found to be Zero order kinetics. 
 
 
Figure 8.42 Ex-vivo Permeation Studies of Formulation F5 
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Table 8.22 Kinetics of ex-vivo Permeation Studies for formulation F5 
Formulation 
No. 
Zero 
Order 
First 
Order 
Higuchi  Peppas  
Best Fit 
Model 
R
2
 R
2
 R
2
 R
2
 n 
F5 0.9936 0.9879 0.9501 0.9926 0.7735 Zero Order 
 
 
Figure 8.43 Best fit model (Zero order) for ex-vivo Permeation Studies of Formulation F5 
 
8.8.9 Stability Studies: 
The best formulation F5 was further subjected to stability studies at room 
temperature. After specified period of stability, the samples were analysed for in-vitro 
drug release and Buoyancy studies. 
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A] In-vitro drug release studies: 
Stability study results of in-vitro drug release study was found to be 83.08 % at 
third month stability testing. When compared with initial results of in-vitro drug release 
study (83.52%), the formulation F5 shows no significant change at room temperature. 
The stability study results of in-vitro drug release study were represented in Table 
8.23, and the respective plot for in-vitro drug release were shown in Figure 8.44.  
Table 8.23 Stability Studies – In-vitro Drug Release for formulation F5 
Time 
(in Hours) 
DURATION* 
Initial 1 month 2 month 3 month 
1 Hour 16.72 ± 0.80 13.13 ± 0.99 13.05 ± 0.30 12.93 ± 0.13 
2 Hours 21.44 ± 0.92 20.83 ± 0.83 20.66 ± 0.72 20.43 ± 0.43 
3 Hours 30.38 ± 1.14 30.22 ± 0.68 30.17 ± 0.51 30.02 ± 0.59 
4 Hours 42.13 ± 1.25 41.61 ± 1.00 41.48 ± 0.83 41.21 ± 1.10 
5 Hours 52.08 ± 1.36 51.40 ± 1.10 51.29 ± 0.88 51.10 ± 1.14 
6 Hours 57.60 ± 1.49 56.90 ± 1.27 56.79 ± 1.15 56.70 ± 1.31 
7 Hours 63.83 ± 2.22 62.89 ± 2.10 62.80 ± 1.91 62.59 ± 1.75 
8 Hours 71.87 ± 2.28 71.49 ± 1.32 71.01 ± 2.06 70.68 ± 1.41 
9 Hours 75.48 ± 1.81 74.78 ± 1.47 74.71 ± 1.34 74.58 ± 1.10 
10 Hours 77.69 ± 1.52 77.18 ± 1.01 77.11 ± 0.87 76.98 ± 0.52 
11 Hours 80.41 ± 1.22 79.38 ± 1.17 79.21 ± 1.03 78.88 ± 0.92 
12 Hours 83.52 ± 0.63 83.48 ± 0.35 83.32 ± 0.35 83.08 ± 0.90 
 
* The values were expressed as Mean ± S.D., n = 3. 
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Figure 8.44 Stability Studies – In-vitro Drug Release 
 
B] Buoyancy Test: 
The stability study results of percentage buoyancy were represented in Table 8.24, 
and the respective plot for percentage buoyancy were shown in Figure 8.45.  
 
Table 8.24 Stability Studies – Buoyancy Test for formulation F5 
Stability Period Initial 1 month 2 month 3 month 
Buoyancy* (%) 
62.56 ± 1.43 62.50 ± 0.62 62.33 ± 0.87 62.19 ± 0.62 
 
* The values are expressed as Mean ± S.D., n = 3. 
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Figure 8.45 Stability Studies – Buoyancy Test 
 
Stability study results of percentage buoyancy was found to be 62.19 % at third 
month stability testing. When compared with initial results of percentage buoyancy 
(62.56 %), the formulation F5 shows no significant change at room temperature.   
 
  
0
10
20
30
40
50
60
70
80
90
100
Initial 1 month 2 month 3 month
P
e
rc
e
n
ta
ge
 B
u
o
ya
n
cy
Time period
  
 
 
 
 
 
 
 
 
 
SUMMARY AND 
CONCLUSION
 Non-effervescent floating microparticulates of Celecoxib Summary and Conclusion 
Adhiparasakthi college of Pharmacy, Melmaruvathur. 129 
9. SUMMARY AND CONCLUSION 
 
 
Celecoxib is the first selective COX-2 inhibitor which is widely used  in the 
treatment of Osteoarthritis, Rheumatoid Arthritis and management of pain. USFDA has 
approved its use Osteoarthritis, Rheumatoid Arthritis with a dose of 100 to 200 mg once / 
twice daily. 
This research work mainly focus on the therapeutic effect of the drug to increased 
bioavailability. According to the BCS classification, Celecoxib is class II compound, 
which is low solubility and high permeability. Oral bioavailability is determined by rate 
of drug release in GI tract.  
Development of new drug molecule was expensive and time consuming. 
Improving safety efficacy ratio of ―old‖ drugs has been attempted using different 
methods such as individualizing drug therapy, dose titration and therapeutic drug 
monitoring. Delivering drug at controlled rate, slow delivery and targeted delivery are 
other very attractive methods. 
Many attempts have been made in recent years to provide a dosage form with 
longer gastro-retention time and therefore a more efficient absorption. Floating drug 
delivery system are well proved and documented to be therapeutically superior to 
conventional dosage system in number of studies. Hence the aim was to develop non 
effervescent floating microparticulates of Celecoxib with the view to prolonged the 
residence time within the GI tract with a controlled release of the drug. 
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The identification of drug was carried out by FTIR spectroscopy and melting 
point. The physicochemical parameters such as color, odor, taste, solubility study and 
loss on drying were performed. The analytical profile of drug was evaluated for 
determination of absorption maximum, development of standard curve and percentage 
purity of drug. 
Compatibility of drug and polymer mixtures were done by performing FTIR and 
DSC study. It was concluded that there were no interaction between drug and polymers. 
Nine different formulations were prepared with different concentration and 
combination of polymers (Ethyl cellulose and HPMC K15M). Celecoxib 
microparticulates were prepared by solvent diffusion and evaporation method.  All the 
formulations were evaluated for Appearance, Percentage yield, Micromeritic properties, 
Particle size, Loss on drying, Buoyancy test, Entrapment efficiency, In-vitro drug release 
and Kinetics of in-vitro drug release.  
On comparing the major criteria in evaluation such as in-vitro drug release, 
Buoyancy percentage and entrapment efficiency, the Formulation F5 showed results of 
in-vitro drug released (83.52%), Buoyancy percentage (62.56%) and entrapment 
efficiency (88.12%), were compared with all formulations F1 to F9. The buoyancy 
percentage, entrapment efficiency and in-vitro drug release of microparticulates were 
increased in formulations with higher ratio of ethyl cellulose. The formulation F5 was 
selected as the best formulation among the nine formulations (F1 to F9) were prepared. 
The kinetics of in-vitro drug release studies were determined by applying the drug 
released data to various kinetic models such as zero order, first order, Higuchi and 
Korsmeyer - Peppas. The formulation F5 was best fitted with first order kinetics. 
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Surface morphology by SEM analysis, ex-vivo permeation study and stability 
studies were carried out for the best formulation F5.  The ex-vivo permeation study was 
performed using membrane obtained from goat stomach. 
All the stability studies for the formulation F5 at room temperature was showed 
no significant change in the percentage drug release studies and percentage buoyancy. 
The formulation F5 was concluded best formulation among the formulations 
were prepared. 
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10. FUTURE PROSPECTUS 
 
 
In the field of gastric retention, there are many obstacles that need to be overcome in 
order to be able to claim true gastric retention. Considering the advantages for improved 
delivery of drugs, further clinical studies are needed to access the utility of this system for 
patients suffering from Rheumatoid arthritis and Osteoarthritis. 
This dosage forms holds promise for further systems. In-vitro – in-vivo correlation 
(IVIVC) will serve as a means of modeling the human organism and of gaining a better 
understanding of drug absorption and its dependence on in-vitro release process. 
Convincing results of clinical studies have yet to be obtained for a gastroretentive 
system that displays the necessary performance behavior and which is retained in the 
fasted stomach of humans for a sensible period of time after dosing. Furthermore, the 
system will need to retain its integrity for an extended period of time in the harsh 
conditions present in the human stomach. 
Once the technology is fully accepted, these systems will probably increase with new 
pipeline drugs that need enhancement to their bioavailability. 
Finally, while the control of drug release profiles has been a major aim of 
pharmaceutical research and development in the past two decades, the control of GI 
transit profiles could be the focus of the next two decades and might result in the 
availability of new products with new therapeutics possibilities and substantial benefits 
for patients. Soon, the novel gastro-retentive products with release and absorption phases 
of approximately 24 hr will surely hit the market. 
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